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1. INTRODUCTION
1.1. Purpose
The European Society for Vascular Surgery (ESVS) appointed
the Descending Thoracic Aorta (DTA) Writing Committee
(WC) to produce the current clinical practice guidelines
document for surgeons and other physicians who are
involved in the overall care of patients with DTA disorders.
The goal of these guidelines is to summarize and evaluate all
current available evidence to assist physicians in selecting the
best management strategies for all DTA pathologies. How-
ever, each respective physician must make the ultimate de-
cision regarding the particular care of an individual patient.
The present guidelines document aims to improve deci-
sion making and decrease variability in the vascular surgical
care of patients presenting with pathology of the DTA.
Unfortunately, robust evidence from prospective and ran-
domized studies is not available for management of most
DTA diseases. Consequently, the recommendations in these
guidelines are entirely based on level B and C evidence.
Nevertheless, when managing DTA pathology, it is clinically
helpful to have access to the most recent and best available
clinical and experimental knowledge to determine the cur-
rent standard of care.
The DTA WC intentionally agreed to exclude pathology of
the ascending aorta and aortic arch from the current
document to avoid potential inter-specialty conﬂict. The
cost analysis of different treatments was also excluded
because of differences in ﬁnancial management and
differing health systems across Europe. Primarily infectious
or mycotic disease processes were also considered outside
of the scope of this document because of their low inci-
dence and poor outcomes.
All disorders originating in the DTA from the left sub-
clavian artery (LSA) origin to the diaphragm were consid-
ered for these guidelines. Pathology involving the thoraco-
abdominal segment of the aorta was also included.
1.2. Methodology
The DTA WC was formed by members of the ESVS from
different European countries, various academic and private
hospitals, and by both vascular surgeons and endovascular
specialists, to maximize the applicability of the ﬁnal guide-
lines document. The DTA Guidelines Committee met in
November 2011 for the ﬁrst time to discuss the purpose,
contents, methods, and timeline of the following
recommendations.
The DTA WC performed a systematic English literature
search in the MEDLINE, EMBASE, and COCHRANE Library
databases for each of the different topics that are discussed
and reviewed. The latest literature search was performed in
ABBREVIATIONS AND ACRONYMS
AAA Abdominal Aortic Aneurysm
AAS Acute Aortic Syndromes
AAST American Association for Surgery of Trauma
AD Aortic Dissection
ATBAD Acute Type B Aortic Dissection
CA Coeliac Artery
CAD Coronary Artery Disease
CCA Common Carotid Artery
COPD Chronic Obstructive Pulmonary Disease
CSF Cerebrospinal Fluid
CT Computed Tomography
CTA Computed Tomographic Angiography
CTBAD Chronic Type B Aortic Dissection
DSA Digital Subtraction Angiography
DTA Descending Thoracic Aorta
DTAA Descending Thoracic Aortic Aneurysm
ECG Electrocardiogram
EDS Ehlers-Danlos Syndrome
EJVES European Journal of Vascular and Endovascular
Surgery
ESR Erythrocyte Sedimentation Rate
ESVS European Society for Vascular Surgery
FL False Lumen
GCA Giant Cells Arteritis
IMH Intramural Haematoma
IRAD International Registry of Aortic Dissection
IVUS Intravascular Ultrasonography
LDS Loeys-Dietz Syndrome
LHB Left Heart Bypass
LSA Left Subclavian Artery
MAP Mean Arterial Pressure
MEP Motor Evoked Potentials
MFS Marfan Syndrome
MRA Magnetic Resonance Angiography
MRI Magnetic Resonance Imaging
NSF Nephrogenic Systemic Fibrosis
OR Open Repair
PAU Penetrating Aortic Ulcer
PET Positron Emission Tomography
PMR Polymyalgia Rheumatica
RCT Randomized Clinical Trial
SCI Spinal Cord Ischaemia
SMA Superior Mesenteric Artery
SSEP Somatosensory Evoked Potentials
TA Takayasu Arteritis
TAAA Thoraco-Abdominal Aortic Aneurysm
TAI Thoracic Aortic Injury
TBAD Type B Aortic Dissection
TEVAR Thoracic Endovascular Repair
TL True Lumen
TOE Transoesophageal Echocardiography
TS Turner Syndrome
TTE Transthoracic Echocardiography
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December 2015. With regard to evidence gathered, the
following eligibility criteria were applied:
 Only peer reviewed published literature was considered
 Published abstracts or congress proceedings were
excluded
 Randomized clinical trials (RCT) as well as meta-analyses
and systematic reviews were assessed with priority
 Non-randomized clinical trials and non-controlled studies
were included
 Well conducted observational studies (cohort and case
control studies) were included
 Previous guidelines, position papers, and published
consensus documents were included as part of the
review process when new evidence was absent
 We minimized the use of reports from a single medical
device or from pharmaceutical companies in order to
reduce the risk of bias across studies.
A grading system was adopted based on the European
Society of Cardiology (ESC) guidelines methodology.1 The
level of evidence classiﬁcation provides information about
the study characteristics supporting the recommendation
and expert consensus, according to the categories shown in
Table 1.
The recommendation grade indicates the strength of a
recommendation. Deﬁnitions of the classes of recommen-
dation are shown in Table 2.
For each recommendation, two members of the WC
assessed the strength of a recommendation and the
quality of supporting evidence independently. A full
master copy of the manuscript with all recommendations
was electronically circulated and approved by all WC
members. Recommendations that required consensus
were discussed and voted on by email among all members
of the WC.
This system permits strong recommendations, supported
by low or very low quality evidence from downgraded RCTs
or observational studies, only when a general consensus is
achieved among the WC members and reviewers.
Two members of the WC prepared each part of the
guidelines document. An internal review process was per-
formed before the manuscript was sent to independent
external reviewers. External reviewers made critical sug-
gestions, comments, and corrections on all preliminary
versions of this guideline. In addition, each member
participated in the consensus process concerning conﬂict-
ing recommendations. The ﬁnal document was reviewed
and approved by the ESVS Guidelines Committee and
submitted to the European Journal of Vascular and Endo-
vascular Surgery (EJVES). Further updated guidelines doc-
uments on DTA management will be provided periodically
by the ESVS when new evidence and/or new clinical
practice arise in this ﬁeld.
To optimize the implementation of the current docu-
ment, the length of the guideline has been kept as short as
possible to facilitate access to guideline information.
Following this decision, the “References” list has been
limited to the most relevant references related to these
guidelines. Nevertheless, an Appendix of recommended
additional references, also reviewed by the WC, has been
added for further information for readers. This clinical
guidelines document was constructed as a guide, not a
document of rules, allowing for ﬂexibility with various pa-
tient presentations. The resulting clinical practice guidelines
provide recommendations for the clinical care of patients
with thoracic aortic diseases including pre-, peri-, and post-
operative care.
Conﬂicts of interest of each WC member were collected
prior to the writing process. These conﬂicts were assessed
and accepted by each member of the WC and are reported
on the ESVS website. In addition, the WC agreed that all
intellectual work should be expressed without any inter-
ference beyond the honesty and professionalism of all
members and assistants during the writing process.
2. GENERAL ASPECTS
2.1. The normal descending thoracic aorta
The DTA originates from the isthmus, the region of the
thoracic aorta between the origin of the LSA and the
ductus arteriosus. The descending thoracic aorta runs in a
left para-spinal location until its distal segment, where it
passes anteriorly through the diaphragmatic aortic hiatus
and inferiorly into the abdomen. Important aortic side
branches originating from the descending thoracic aorta
Table 1. Levels of evidence.1
Level of Evidence A Data derived from mulple 
randomized clinical trials or meta-
analyses 
Level of Evidence B Data derived from a single randomized 
clinical trial or large non-randomized 
studies 
Level of Evidence C Consensus of opinion of the experts 
and/or small studies, retrospecve 
studies, or registries 
Table 2. Grades of strength of recommendations according to the
ESC grading system.1
Classes of 
recommenda?on 
Defini?on 
Class I Evidence and/or general agreement that a 
given treatment or procedure is beneficial, 
useful, eﬀecƟve. It should be performed
Class II ConflicƟng evidence and/or a divergence of 
opinion about the usefulness/eﬃcacy of the 
given treatment or procedure 
Class IIa Weight of evidence/opinion is in favour of 
usefulness/eﬃcacy. It should be considered
Class IIb Usefulness/eﬃcacy is less well established by 
evidence/opinion. It may be considered
Class III Evidence or general agreement that the given 
treatment or procedure is not 
useful/eﬀecƟve, and in some cases may be 
harmful. It is not recommended
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include the intercostal arteries, spinal arteries, and bron-
chial arteries. The normal diameter of the mid-descending
aorta ranges from 24 to 29 mm in men and 24 to 26 mm in
women, whereas the normal diameter at the level of the
diaphragm is 24 to 27 mm in men and 23 to 24 mm in
women. Aortic diameter is inﬂuenced by age and body
mass index.2,3
The aortic wall is composed of three layers: the intima,
media, and adventitia. The intima, the innermost layer,
consists of an endothelial monolayer and an internal
elastic lamina. Because it is in direct contact with blood,
the function of the intima is to prevent thrombosis and
atherosclerosis. Its anti-thrombotic and anti-atheroscle-
rotic function can be reduced by risk factors, such as
smoking, hypertension, hyperlipidaemia, diabetes, and
direct trauma, each making patients more prone to aortic
disease.
The media consists of concentric layers of elastin,
collagen, and smooth muscle cells. These components are
responsible for aortic wall elasticity, which accommodates
the changes in stroke volume during the cardiac cycle,
converts pulsatile inﬂow into a smoother outﬂow (Wind-
kessel function), and maintains the integrity of the aortic
wall. Congenital or hereditary disorders (e.g. bicuspid aortic
valve, Marfan syndrome [MFS], Ehlers-Danlos syndrome
[EDS]), risk factors (hypertension, atherosclerosis, and
trauma) all inﬂuence aortic wall function. These conditions
can stiffen the aortic wall, decreasing its ability to accom-
modate the stroke volume, resulting in systemic hyperten-
sion, or weakening of the aortic wall, leading to dilatation or
dissection.
The adventitia is the outermost layer of the aortic wall
and is composed mainly of collagen ﬁbres, external elastic
lamina, and small vessels (the vasa vasorum), which pro-
vide the blood supply to the aortic wall and surrounding
nerves.
2.2. Epidemiology of descending thoracic aortic disease
DTA diseases consist of a broad spectrum of degenerative,
structural, acquired, genetic, and traumatic disorders. The
true incidence of descending thoracic aortic pathology re-
mains unclear. Epidemiological studies are sparse and it is
likely that many DTA related deaths are attributed to other
cardiovascular diseases, such as cardiac arrest, myocardial
infarction, cerebrovascular accidents, or abdominal aneu-
rysm rupture. Therefore, the overall incidence of DTA dis-
ease is likely to be underestimated.
The pathophysiology of thoracic aortic diseases is
believed to be multifactorial, resulting both from genetic
susceptibility and environmental exposure. Therefore, the
incidence of the different thoracic aortic diseases can vary
signiﬁcantly among different population groups.
Acute aortic syndromes (AAS) consist of three interre-
lated diseases: aortic dissection, penetrating aortic ulcer
(PAU), and intramural haematoma (IMH). Type B aortic
dissection (TBAD) most commonly affects male patients and
has an incidence between 2.9 and 4.0 per 100,000 person-
years.4 The incidence of TBAD seems to be increasing. A
recent prospective analysis of 30,412 middle aged men and
women from Malmö, Sweden with a 20 year follow up re-
ported an incidence of acute aortic dissection of 15 per
100,000 patient years.5 This increase is probably caused by
the increasing age of the population and improving diag-
nostic modalities. The exact incidence remains unknown,
but PAU has been diagnosed with increasing frequency
because of the widespread use of advanced cross sectional
imaging techniques. In symptomatic patients suspected of
AAS, the prevalence of PAU is 2.3e7.6% and the lesion is
localised in the DTA in 90% of patients.6 IMH may be
related to PAU, accounting for 5e20% of patients with AAS
and more commonly involving the DTA (60%) than the
ascending aorta.7
Trauma is the leading cause of death during the ﬁrst four
decades of life, accounting for more than 250,000 deaths
every year in the European Union alone.8 Blunt aortic injury
is the second leading cause of death in these patients, and
although it occurs in less than 1% of all motor vehicle ac-
cidents, it accounts for 16% of all traumatic deaths.9
Concerning ruptured descending thoracic aortic aneu-
rysm (DTAA), a Swedish population study reported an
incidence of 5 per 100,000 person-years. The mean age of
patients in this cohort was 70 years for men and 72 years
for women.10
Aneurysmal dilatation of the DTA is a degenerative dis-
ease with an estimated incidence of 6e10.4 per 100,000
person-years. The incidence seems to be increasing with
ageing of the general population and continually improving
diagnostic modalities.11
Aortitis is a relatively uncommon disorder with a broad
spectrum of clinical features. The most common autoim-
mune disorders affecting the DTA are Takayasu’s arteritis
(TA), giant cell arteritis (GCA), and Behçet’s disease. The
best estimates of the incidence of TA suggest that two or
three cases occur each year per million people.12 There is a
9:1 female to male predominance. Although the disease has
a worldwide distribution, it appears to occur more
frequently in Asian women.
GCA is the most common type of vasculitis observed in
patients older than 50 years. Predominantly observed in
populations of Scandinavian descent, it has a reported
prevalence that varies between 1 and 30 per 100,000
people.13 The male to female ratio is around 2.5 to 1 and is
highly dependent on geographic and genetic parameters.14
Behçet’s disease has been observed most commonly
along the classic Silk Route, with a peak prevalence in
Turkey of 80e370 per 100,000 people, compared with 1e3
per million people in the Western world. Presentation is
typically in the third to ﬁfth decade of life, and both genders
are affected equally.15
Coarctation of the aorta is a congenital cardiovascular
defect, most commonly occurring at the level of the
isthmus and accounts for 5e8% of all congenital heart
defects. The overall incidence ranges between 20 and 60
per 100,000 person-years, with a slight male predominance.
Patients with Turner syndrome (TS) are more commonly
affected.16
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2.3. Diagnostic methods in descending thoracic aortic
disease
2.3.1. Medical history and physical examination. A
comprehensive medical and family history, assessment of
symptoms, and careful physical examination including blood
pressure measurement and electrocardiography (ECG), are
required in all patients suspected of thoracic aortic disease.
Patients should be examined for suspicious clinical signs
such as aortic regurgitation, cardiac murmur, pericardial
rub, signs of tamponade, and an expansile abdominal aorta.
The diagnosis of thoracic aortic disease is based on imaging
and the choice of imaging modality should be based on the
patient’s condition and the availability of different imaging
modalities.17
2.3.2. Plain radiography. Postero-anterior and lateral chest
radiographs can be used to diagnose calciﬁcation within
atheromatous lesions, left pleural effusions, aortic enlarge-
ment, and anomalous aortic contours in asymptomatic or
symptomatic patients. A left pleural effusion can indicate a
frank rupture, an exudate from inﬂammation of the adven-
titia in AAS, or, less commonly, inﬂammatory aortic disease.
The International Registry of Acute Aortic Dissection (IRAD)
showed that 21% of patients with a type B aortic dissection
presented with a normal chest X-ray, and a meta-analysis
demonstrated a sensitivity for an abnormal chest X-ray of
90% for TBAD.18 Although chest X-rays might be used in very
low risk patients to exclude thoracic aortic diseases, these
potentially lethal diseases require a conclusive diagnosis
with the use of multiplanar imaging techniques such as
computed tomographic angiography (CTA).
2.3.3. Transthoracic echocardiography. The use of TTE to
assess the DTA is limited by structures in the thorax that
weaken or distort the ultrasound signal and compromise im-
age quality. Via a suprasternal, subcostal, or parasternal view,
small parts of the DTA can be visualized, while in the case of a
pleural effusion, the back of the patient can be used for
transthoracic imaging.19 The major advantage of TTE is that it
is non-invasive and can be used to visualize the ascending
aorta, aortic arch, and supra-aortic vessels. In addition, the
abdominal aorta can be visualized to check for abdominal
extension of aortic dissection (AD). During TTE, all planes
should be used to assess the extent of aortic disease and to
exclude additional aortic or cardiac involvement. Because of
its non-invasive nature andwide availability,TTE is increasingly
used in the emergency department of community hospitals to
screen patients suspected of having one or other acute aortic
syndrome, such as typeAdissection. However, the value of TTE
in the diagnosis of DTA pathology remains limited. In cases of
examination limitations or inconclusive diagnosis, the use of
additional imaging modalities is recommended.19 There are
currently no speciﬁc studies to validate the usefulness of TTE
for diagnosis of DTA pathology.
2.3.4. Transoesophageal echocardiography. TOE can visu-
alize the DTA from the LSA to the coeliac artery (CA). This
diagnostic test is generally used as a second line imaging
modality and is useful to differentiate between AD, IMH,
and PAU.With a reported sensitivity of 98% and a speciﬁcity
of 95%, TOE is an accurate diagnostic tool for aortic disease,
providing functional information in both the pre- and intra-
operative settings.19 The semi-invasive nature of TOE has
rare procedure related risks, but it can cause patient
discomfort, requires sedation, and is contraindicated in the
presence of oesophageal pathologies. In the majority of
cases, computed tomographic angiography (CTA) scanning
is performed as the ﬁrst imaging modality, providing all
required information. TOE may be used in speciﬁc circum-
stances as a second line option.
2.3.5. Computed tomographic angiography. CTA offers a
detailed visualisation of the entire aorta and its surrounding
structures. It can distinguish different aortic pathologies and is
quick andwidely available. Over the last two decades, CTA has
become more sophisticated and is more readily available,
with an increase in the number of scanners, the use of
retrospective and prospective ECG-gated techniques, and
through advances in post-processing software. These ad-
vances have resulted in motion free images with better res-
olution, reduced scanning times, and better visualisation.20
Current CTA scanners have a sensitivity of up to 100%
and a speciﬁcity of 98e99%, with slight variations between
different DTA pathologies.21 Imaging should include a non-
contrast study, followed by an early and late phase contrast
study and should examine the part of the body between the
thoracic inlet and the common femoral arteries. This range
provides complete information with three dimensional
reconstruction. In addition, dynamic images can further
assist in surgical planning or endovascular interventions.
Consequently, CTA has replaced digital subtraction aortog-
raphy as the “gold standard” for aortic imaging. Important
disadvantages of CTA include the use of nephrotoxic
contrast agents and the exposure of patients to ionizing
radiation. In patients at increased risk of contrast induced
nephropathy, circulating volume expansion with either
isotonic sodium chloride or sodium bicarbonate solutions is
recommended.22
ClassRecommenda?on 1 Level of evidence References
All paƟents with clinical suspicion of thoracic aorƟc disease and
abnormal chest radiograph should undergo computed tomographic
angiography for diagnosis confirmaƟon.
I C 17,18
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2.3.6. Magnetic resonance imaging. MRI has an excellent
diagnostic capability that is comparable with CTA and TOE
and can be used for both pre-operative planning and follow
up.23 A major advantage of MRI is that it offers multiplanar
evaluation with good differentiation between different soft
tissues. Moreover, MRI can provide additional dynamic
imaging regarding entry tear ﬂow or arterial vessel
involvement.23 Although contrast is not usually required,
the use of gadolinium enhances the quality of MRI. MRI can
be used to visualize the aortic wall in detail and is, there-
fore, more commonly used in patients with aortic wall pa-
thologies such as IMH or aortitis. Furthermore, MRI does
not require ionizing radiation and offers an alternative for
patients with renal insufﬁciency in some circumstances.
Important disadvantages of MRI include its limited
availability and longer scanning times, which makes it less
suitable for critically ill or unstable patients. In addition, the
ability of MRI to detect calciﬁcation is decreased (compared
with CTA), and artefacts from respiration or metallic im-
plants reduce image quality. Post-gadolinium nephrogenic
systemic ﬁbrosis (NSF) is a rare, but devastating, side-effect
in patients with impaired renal function. Using alternative
imaging modalities or using the lowest possible amount of
gadolinium may prevent NSF.24
2.3.7. Positron emission tomography. PET is a nuclear im-
aging modality that is based on the detection of increased
metabolic activity in inﬂammatory cells, resulting in increased
uptake of a gammagraphic tracer, most commonly ﬂuo-
rodeoxyglucose ([18F] FDG). PET can be used for the diagnosis
of aortitis and in the assessment of the extent and activity of
any inﬂammatory disease. The diagnostic value of FDG-PET
differs among the various inﬂammatory aortic diseases with
a reported sensitivity ranging between 83% and 100% and
speciﬁcity between 77% and 100%.25 Development of PET in
combination with computed tomography (CT) scanners has
made it possible to combine functional and anatomic imaging,
thereby making it possible for PET ﬁndings to be correlated
with adjacent anatomical features. Although the availability of
PET and PET/CT is limited, this modality may be used for
diagnosis and follow up of aortitis.26 Increased patient
radiation exposure is a major disadvantage of PET/CT (when
comparedwith PETor CT examinations alone), as the effective
radiation dose is a combination of the dose fromboth scans.27
2.3.8. Intra-vascular ultrasonography. IVUS permits 360
visualisation of the aortic wall. It can be very helpful in
conﬁrming intimal defects when CTA and digital subtraction
angiography (DSA) are inconclusive in the diagnosis of aortic
injuries. IVUS is an operator and experience-dependent
invasive procedure, and a complete evaluation of the
aorta using IVUS can be time consuming. In some centres,
IVUS is routinely used as an adjuvant imaging technique
during endovascular repair (see also Section 3.1.4.1).
Table 3 compares different imaging diagnostic tests for DTA
according to their features and performance.
2.4. Neurological complications: prevention and
management
The most feared and devastating complications associated
with management of DTA disease are spinal cord ischaemia
(SCI), resulting in paraparesis or paraplegia, and cerebral
embolism, resulting in stroke.28 SCI can develop immedi-
ately after surgery or with a delayed presentation.
Although SCI rates as high as 20% have been reported, the
incidence probably ranges between 2% and 6%.29 The
incidence of paraplegia is related to the duration and de-
gree of spinal ischaemia resulting from an abrupt cessation
of blood ﬂow to the spinal cord and from a reperfusion
injury mediated by biochemical mediators.30 The presence
of stroke after DTA surgery seems to be similar to aortic
arch repair and often has an embolic aetiology, with an
incidence up to 8% in elective cases or higher in the
emergency setting.31 Classic predictors for these compli-
cations are diverse and include increasing patient age,
previous carotid artery disease, aortic cross-clamp time, the
extent of the aortic resection, aortic rupture, concurrent
aneurysm disease of ascending aorta and/or aortic arch,
emergency surgery, the use and duration of hypothermic
arrest, peri-operative hypotension, and pre-operative renal
dysfunction.28,31
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Several methods for spinal cord and brain protection
have been used to reduce the incidence of neurological
complications. These methods are described in the
following sections.
2.4.1. Spinal cord function monitoring. During thoracic
aortic surgery, the function of the spinal cord can be directly
monitored with use of somatosensory evoked potentials
(SSEP) or motor evoked potentials (MEP).30 SSEP monitoring
records stimulation of the posterior tibial nerve by elec-
trodes placed on the scalp, and this technique is sensitive
for detecting spinal cord ischaemia. Clinical studies have
shown that SSEP can be used both to identify dominant
intercostal arteries and to determine if these vessels require
re-implantation.32 However, SSEP does not record motor
function because perfusion of the anterior corticospinal
tract is not assessed. Therefore, SSEP can be associated with
delayed detection of ischaemia, thereby reducing its spec-
iﬁcity.30 MEP, on the other hand, stimulates the cortico-
spinal tract transcranially or via the spinal cord directly. This
technique has demonstrated increased sensitivity in pre-
dicting SCI compared with SSEP.33,34 Major disadvantages of
MEP are the inﬂuence of anaesthetic agents on the po-
tential amplitude and the resistance of axonal conduction to
ischaemia, which makes the response of MEP to ischaemia
generally slow.33 Institutional experience and availability of
these techniques should determine their use.
2.4.2. Prevention of spinal cord ischaemia in open repair.
Surgical techniques have been developed over the years to
prevent SCI. Techniques like the Crawford inlay, single clamp
repair, sequential aortic clamping, and others have been
introduced with varying results. As revascularisation of all of
the intercostal arteries is not feasible, the identiﬁcation of
important vessels is relevant for success.35 Revascularisa-
tion of the artery of Adamkiewicz and the intercostal ar-
teries of T11/T12 has been reported, although not widely
implemented. Pre-operative angiography has been used to
identify the most important vessels, but as angiography it-
self can induce SCI (resulting from embolisation), other
modalities such as magnetic resonance angiography (MRA)
and CTA have become more popular.36
Cerebrospinal ﬂuid (CSF) pressure increases with aortic
cross-clamping, and will eventually exceed the venous pres-
sure, compromising venous outﬂow, leading to spinal cord
malperfusion and secondary SCI. Randomized controlled
trials and meta-analyses have shown that CSF drainage has a
role in the prevention of paraplegia and paraparesis, with a
risk reduction up to 75% (OR 0.48, 95% CI 0.25e0.92), but
additional studies are recommended.29,37
During aortic cross-clamping, prophylactic CSF drainage
aims to maintain CSF pressure at 10 mm Hg intra-
operatively and for 48e72 hours after completion of the
aneurysm repair. In fact, delayed and late onset of neuro-
logical deﬁcit are also described and potentially worsened
by haemodynamic instability.35
Recent studies have shown that CSF drainage combined
with intrathecal papaverine solution can be beneﬁcial.38 Po-
tential complications related to CSF drainage occur in fewer
than 5% of cases, and include meningitis, epidural haema-
toma, subdural haematoma, and CSF leakage syndrome.37e39
The use of left heart bypass (LHB) prevents heart failure
and maintains distal aortic perfusion and CSF pressures as
close to baseline as possible, and thereby reduces the risk of
post-operative paraplegia and paraparesis in patients un-
dergoing repair of type I and type II thoraco-abdominal
aortic aneurysm (TAAA)40 (see also Section 3.4.). Extra-
Table 3. Comparison of different imaging modalities for DTA diagnosis.17
Characteristics TTE TOE CTA MRI PET IVUS
Non-invasiveness þþþ þþ  þ  
Ease of use þþþ þþ þþþ þþ þþ þ
Availability þþþ þþ þþþ þþ þ þ
Portability/bedside use þþþ þþþ    þ/
Interventional guidance use þ þþþ    þþþ
Safe for serial examinations þþþ þþ þþ þþþ þþ 
Wall contour assessment þ þþþ þþþ þþ þþ þþ
Supra-aortic vessel status evaluation þþ þ þþþ þþþ þþ þþ
Aortic valve status evaluation þþþ þþþ    
Pericardial effusion detection þþþ þþþ þþþ þþþ þþ 
Inﬂammation/Infection detection  þ þþ þþ þþþ þ
Number of signs (þ or ) represents the estimated potential value.
TTE ¼ transthoracic echocardiography; TOE ¼ transoesophageal echocardiography; CTA ¼ computed tomographic angiography;
MRI ¼ magnetic resonance imaging; PET ¼ positron emission tomography; IVUS ¼ intra-vascular ultrasonography.
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corporeal circulation allows sequential aortic clamping,
maintaining retrograde perfusion of all of the vital organs
and the spinal cord. These techniques have been shown to
be beneﬁcial in patients with TAAA, reducing the incidence
of SCI by perfusion of the distal aorta from 11.2% to 4.5%.40
Another important advantage of circulatory bypass is that it
permits the induction of systemic hypothermia for addi-
tional neurological protection. Distal perfusion is often
combined with CSF drainage or hypothermia, and has
proven beneﬁcial in reducing the incidence of SCI.35,38,41
Induced systemic hypothermia by cardiopulmonary bypass
and intermittent cardiac arrest might be an effective
method to reduce the risk of SCI.41 Moderate systemic
hypothermia to temperatures of 32 C improves outcome
without signiﬁcant risks for the patient.41,42 However, the
systemic anticoagulation required in these patients in-
creases the risk of bleeding, and, in such conditions, CSF
drainage and intrathecal manoeuvres can be
dangerous.39,41,42 During the post-operative period, the
maintenance of mean arterial pressure (MAP) between 80
and 100 mm Hg has been suggested by high volume
centers.35
After a period of ischaemia caused by cross-clamping,
reperfusion injury can occur. Biochemical mediators, espe-
cially iron-related free radicals, induce cellular damage.
Free radical scavengers have been studied in the
prevention of ischaemia, which suggests that numerous
agents may protect the spinal cord from transient
ischaemia.43
Other pharmacological agents such as glucocorticoste-
roids may be beneﬁcial in the prevention of SCI, although
high quality evidence is lacking.44 Other options include
intrathecal hypothermia, but this requires an open lam-
inectomy or closed epidural infusion system. These tech-
niques are not fully applicable in current clinical practice
(see also Sections 3.1, 3.2, 3.3, and 3.4 for speciﬁc details).
2.4.3. Prevention of spinal cord ischaemia in thoracic
endovascular repair. TEVAR has been associated with a
reduced incidence of neurological complications compared
with open DTAA repair, but the risk of paraplegia or para-
paresis ranges from 2.5% up to 8% and remains a
concern.44e46 Prior abdominal aorta aneurysm (AAA) repair,
prolonged hypotension, severe atherosclerosis of the
thoracic aorta, occlusion of the left subclavian artery and/or
hypogastric arteries, and extensive coverage of the thoracic
aorta by the endograft are all associated with an increased
incidence of SCI.44e49 Therefore, spinal cord protection
(including CSF drainage) should be considered in patients
with previous AAA repair or in patients who require
extensive aortic repairs, as the beneﬁt of CSF drainage is
greatest in patients at the highest risk for spinal cord
injury.45e47
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2.4.4. Prevention of stroke. Intra-operative embolism is the
main cause of stroke in patients undergoing surgical repair
of the DTA, emphasizing the importance of precautions
during the operative period.
Debris from aortic atheroma/thrombus can result in an
embolic ischaemic stroke and the release of debris should
be prevented during surgery. Reducing manipulation of the
DTA to a strict minimum40 and TOE mapping of the sites of
cannulation are techniques that can minimize the risk of
embolisation.19 When clamping is neither possible nor
recommended, deep hypothermic circulatory arrest must
be instituted.42 In patients with atrial ﬁbrillation, the use of
arteriovenous femoro-femoral bypass or deep hypothermic
arrest and the avoidance of cannulation of the left atrium
with possible manipulation of thrombus may be a useful
alternative.40,42
During endovascular repair, guidewires within the aortic
arch have the potential to mobilize debris and guidewire
manipulation should be reduced to the minimum. Accord-
ing to a recent retrospective, multicentre analysis of se-
lective LSA revascularisation in the treatment of multiple
DTA pathologies,48 coverage of the LSA in patients treated
with TEVAR was associated with a higher incidence of stroke
and paraplegia. Therefore, LSA revascularisation should be
considered in the elective setting.44e46,49,50 In the acute
setting, revascularisation should be performed based on the
patient’s anatomy (left mammary to coronary bypass, or
dominant cerebral blood supply from the left vertebral ar-
tery) during emergency repair of the DTA (see also Sections
3.1 and 3.3).
3. SPECIFIC THORACIC AORTIC DISORDERS
3.1. Acute thoracic aortic syndrome
AAS covers a heterogeneous group of patients with similar
anatomic and clinical characteristics. This group includes AD,
IMH, and PAU.51 Traumatic aortic transection and ruptured
DTAA also may be included. The most common symptom is
chest pain. Histopathologically, all of these entities involve
disruption of the media of the aorta, with bleeding between
the layers of the aorta or transmurally in the case of rupture.
Each condition can progress to another one of the group
and each pathology may coexist in the same patient.
3.1.1. Acute type B aortic dissection.
3.1.1.1. Deﬁnition, risk factors, and clinical presentation.
Acute type B aortic dissection (ATBAD) is the result of a tear
in the intimal arterial layer, which allows blood to propagate
within the medial layer. This creates a ﬂap, which divides
the aorta into a true lumen (TL), and a false lumen (FL). The
most common site for the proximal intimal tear in ATBAD is
located just distal to the origin of the left subclavian artery.
In 90% of cases, ATBAD has a secondary tear that allows
blood to re-enter the TL at what is known as the re-entry
site.51,52
The Stanford and DeBakey classiﬁcations are most
commonly used to describe ATBAD (Fig. 1). DeBakey clas-
siﬁed AD, based on the origin of the intimal tear and the
extent of the dissection. The Stanford classiﬁcation is based
on the involvement of the ascending aorta.53 A type A
dissection is deﬁned by involvement of the ascending aorta
and type B by the absence of ascending aortic involvement.
There is no consensus about the classiﬁcation of arch AD
without involvement of the ascending aorta.54 Type B dis-
sections originate distal to the ostium of the left subclavian
artery. This classiﬁcation is comparable with a DeBakey type
III (including type IIIb), in which the dissection extends into
the abdominal aorta. ATBAD accounts for 30e40% of all
dissections.52,54e56 AD is deﬁned as “acute dissection”
within 14 days of the onset of symptoms. Thereafter, it is
deﬁned as sub-acute between 2 weeks and 3 months and
chronic after 3 months (see also Section 3.2).
Any condition that increases intimal shear stress or
decreases arterial wall strength is considered to be a risk
factor. Systemic hypertension is present in almost 80% of
ATBAD patients.51 Increasing age and atherosclerosis are
other important risk factors,57 as are congenital bicuspid
or uni-commissural aortic valves,58 cocaine abuse,59
pregnancy,60 strenuous activities, and severe emotional
stress.61
ReferencesLevel of evidenceClassRecommenda?on 11
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Figure 1. Schematic drawings of De Bakey (I, II, IIIa and IIIb) and
Stanford (A and B) combined classiﬁcations for aortic dissection.
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Another important risk factor is a positive family history
of thoracic aortic diseases. ATBAD has a prevalence of 13e
22% in patients who have a ﬁrst degree relative with a
history of DTAA or AD.62 The “familial thoracic aorta and
dissection syndrome” is related to several identiﬁed gene
mutations, including ﬁbrillin-1 (FBN1), transforming growth
factor-b1 (TGFBR1), transforming growth factor-b2
(TGFRB2), a-actin 2 (ACTA 2), and myosin heavy chain 11
(MYH11), increasing insight into the genetic pathology of
the disease.63,64
Structural weakness of the aortic wall is associated with
multiple connective tissue disorders such as MFS, EDS, and
Loeys-Dietz syndrome (LDS) (see also Section 3.7). In pa-
tients younger than 40 years of age, who present with
aortic dissection, about 50% will have MFS or a related
genetic disorder. This group of patients, as well as those
with a family history of thoracic aortic diseases, should
receive genetic counselling.62 The aortic diameter is not
closely related to ATBAD, although an increased risk of
ATBAD has been observed in patients with a dilated DTA.65
The mean diameter in ATBAD has been reported as
41 mm.66 Indeed, many cases of ATBAD can occur in pa-
tients with normal diameter aortas.66,67
The clinical presentation of patients presenting with
ATBAD can be diverse and may mimic a wide range of other
disorders. The classical presentation is acute onset excru-
ciating chest or interscapular pain, which is present in about
80% of ATBAD patients.55,60 The main clinical signs and
symptoms are reported in Table 4. The IRAD showed that
hypotension (OR 23.8, 95% CI 10.31e54.94, p < .0001),
absence of chest/back pain (OR 3.5, 95% CI 1.3e9.52,
p ¼ 0.01), and branch vessel involvement (OR 2.9, 95% CI
1.21e6.99, p ¼ 0.02) are predictors of in hospital
mortality.60 Although most patients present with these
symptoms, some may have a non-speciﬁc presentation or
even no symptoms, which can delay the diagnosis.68,69 For
that reason, physicians must be familiar with an atypical
presentation and a low threshold for diagnostic imaging
should be maintained.
The most severe ATBAD complications include aortic
rupture and occlusion of arterial branches, with conse-
quent loss of arterial perfusion. Aortic rupture is associated
with a high mortality, irrespective of the type of treat-
ment,52,70e73 whereas patients with impending rupture
who have no haemodynamic complications have better
outcomes.56,70
Renal and/or visceral ischaemia may be difﬁcult to detect.
Renal ischaemia can increase creatinine levels and potentially
induce refractory hypertension.Treatment of renal ischaemia
is important to prevent permanent renal insufﬁciency and
refractory hypertension which is likely to result in a more
rapid expansion of the affected aorta.Visceral ischaemia was
the third most common cause of death (after aortic rupture
and tamponade) in AD patients in the IRAD study,55 and can
result from malperfusion or systemic hypotension.55,56,60
Serum lactate levels are elevated when the ischaemic injury
progresses or becomes irreversible; therefore early diagnosis
is essential. ATBAD patients who present with or who
develop recurrent abdominal pain should undergo repeat
cross sectional imaging. In this situation, there should be a
low threshold for undertaking laparoscopic inspection of the
peritoneal cavity.74 Gastrointestinal haemorrhage is a rare
complication and every patient presenting with bleeding and
abdominal pain should be suspected of having mesenteric
ischaemia.75
Acute limb ischaemia may present with paralysis of one
or both lower limbs. Because of the dynamic nature of the
dissection membrane, the presence of palpable peripheral
pulses may be misleading.76
Paraplegia/paraparesis represents a catastrophic, but
rare, complication of ATBAD secondary to SCI. Other com-
plications include refractory pain and refractory hyperten-
sion, which are both indirect signs of impending rupture
and are associated with increased in hospital mortality.77
Complicated ATBAD is deﬁned as the presence of rapid
aortic expansion, aortic rupture and/or hypotension/shock,
visceral, renal, or limb ischaemia, paraplegia/paraparesis,
peri-aortic haematoma, recurrent or refractory pain, and
refractory hypertension despite adequate medical therapy.
In hospital survival in complicated ATBAD patients
treated conservatively is about 50%.55,56,60,65,70e72,78
Hypotension/shock and visceral ischaemia are considered
the most important predictors of in hospital death.56,60
Table 4. Main clinical presentations of ATBAD.
Signs and symptoms Incidence, %
Acute excruciating chest or
interscapular pain
80
Chest pain 79
Back pain 64
Abdominal pain 43
Syncope 4
Pulse deﬁcits 9
Hypotension/shock 4
Visceral ischaemia 7
Renal ischaemia 15
Limb ischaemia 9
Recurrent pain, refractory
pain, or refractory hypertension
18
Spinal cord ischaemia 3
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Complicated ATBAD patients with severe comorbidities
(e.g. ischaemic heart disease, chronic pulmonary disease, or
malignancy) may not beneﬁt from invasive management
and should be evaluated individually.65,70,78
ATBAD may also present without complications in almost
50% of cases. This cohort is deﬁned as uncomplicated
ATBAD.55,78 Despite the absence of complications at the
time of presentation, these patients have an in hospital
mortality of 3e10%.55,78 In the presence of complications
(such as visceral, renal or limb ischaemia, and/or aortic
rupture), mortality rises to 20% by day 2 and 25% by day 30.
Like type A dissection, advanced age, rupture, shock, and
malperfusion are important predictors of increased early
mortality.60,79
3.1.1.2. Management. The aims of treating ATBAD are to
maintain or restore perfusion of the vital organs and to
prevent both progression of the dissection and aortic
rupture. Therefore, it is important to make a risk assessment
at an early stage to determine the merits of medical,
endovascular, or surgical intervention.
3.1.1.2.1. Medical management. Medical therapy with
antihypertensive agents is widely accepted to be the ﬁrst
line treatment in uncomplicated ATBAD patients.52,54e56,
60,65,70,77e79 Medical management is based on blood
pressure reduction to limit aortic wall stress and to reduce
the force of left ventricular ejection.72 The goal is to
reduce systolic blood pressure between 100 and 120 mm
Hg and, when attainable, the heart rate below 60 beats/
min.54 In ATBAD, initial medical therapy consists of b-
blockers.55,79,80 In patients who do not respond to b-
blockers or who do not tolerate the drug, calcium channel
antagonists and/or renin-angiotensin inhibitors can be
used as alternatives.80e83 b-blockers and calcium channel
blockers have been associated with improved long-term
survival in ATBAD patients.83 Recent data have shown
that angiotensin II type 1 receptor blockers have similar
positive effects to atenolol in terms of growth reduction
of the aortic root in children and young adults with
MFS.81,82 Other alternative therapies include sodium
nitroprusside, A1-adrenergic, and non-selective
b blockers.84
Pain relief is also an important component of optimal
medical therapy, as persisting pain may indicate progression
of the dissection or impending rupture, requiring additional
therapy.77
During hospitalisation, all IV medications should be
converted into oral agents, and long-term blood pressure
regulation with adequate surveillance is mandatory.
3.1.1.2.2. Endovascular repair. TEVAR has developed as the
ﬁrst line therapeutic option in patients with complicated
ATBAD.85e95 The aim of endovascular repair for treating
impending aortic rupture or malperfusion is to cover the
primary entry tear and to reduce blood pressure within the
FL.90,95 Reduction in FL perfusion can prevent extension of the
dissection, which may lead to FL thrombosis, aortic remod-
elling, and aortic wall stabilisation.
Although there are no randomized controlled trials, there
is increasing evidence that in complicated ATBAD, emergency
and urgent interventions have been beneﬁcial.55,60,77,86,87 In
these settings, TEVAR has shown a substantial advantage
over OR in terms of early mortality.87e89,92e94
Currently, there are three meta-analyses available that
report short- and mid-term results in complicated ATBAD
patients treated with TEVAR. Technical success ranged from
95% to 99%, hospital mortality ranged from 2.6% to 9.8%, and
neurological complications ranged from 0.6% to 3.1%.6,96,97
A prospective, multicentre European clinical registry
showed a 30 day mortality of 8%, a stroke rate of 8%, and a
SCI rate of 2% in 50 ATBAD patients.98 The initial results of a
single arm multicentre study for endovascular repair of
complicated AD, using a composite device design (PETTICOAT
technique), which includes an uncovered infra-
diaphragmatic aortic stent in addition to a standard TEVAR,
showed a 1 yearmortality of 10%. Stroke, transient ischaemic
attack, or progression of dissection occurred in 7.5%, 2.5%,
and 5% of patients, respectively.99 Another study conﬁrmed
these ﬁndings with an in hospital mortality of 4%, 40%, and
33% in TEVAR, OR, and medically treated patients, respec-
tively.87 However, there is no evidence that extended
coverage of the DTA is needed to restore distal perfusion.
Among complicated ATBAD patients, those presenting
with visceral malperfusion experience the poorest
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outcomes. Although visceral vessel patency following TEVAR
is maintained in up to 97% of patients, the 30 day mortality
is high (17e34%), as are aortic related complications during
the chronic stage.67,89
These patients seem to beneﬁt from aortic balloon
fenestration and branch stenting.100e102 A dynamic
obstruction can be managed by increasing FL outﬂow with
fenestration of the intimal ﬂap, while a static obstruction or
ostial disruption should be treated by stenting of the mal-
perfused branch vessel.73,100e102
TEVAR has also been advocated in the treatment of un-
complicated ATBAD, to prevent long-term aortic dilatation
and rupture. IRAD reported reduced mortality at 5 years in
ATBAD patients treated by TEVAR, compared with those
managed medically.103 ADSORB, the only randomized con-
trol trial in patients with uncomplicated ATBAD, was not
sufﬁciently powered for mortality at 1 year follow up. This
trial did, however, show higher rates of FL thrombosis in
patients randomized to TEVAR, and FL thrombosis is asso-
ciated with fewer late complications and increased aortic
remodelling following repair of ATBAD.104
Although TEVAR results in this setting are favourable,
endovascular related complications can be devastating and
may require revision with OR.105 Stroke is reported to occur in
3e10% of patients undergoing TEVAR because of manipula-
tion of catheters in the arch and ascending aorta, and occurs
more commonly in patients with severe arch atheroscle-
rosis.44 Although rare in ATBAD patients, SCI is related to the
extent of aortic coverage, history of previous aortic surgery
and the presence of hypotension at initial presentation.47
Arm ischaemia, paraparesis, and paraplegia may occur from
LSA or intercostal artery occlusion, which may require revas-
cularisation.49,50 (see Section 2.4.4). Other complications
(device or procedure related) can include aortic rupture
during deployment, angulation, migration, or collapse of the
stent graft, false aneurysm formation at the proximal or distal
end of the stent graft, graft erosion, or stent frame frac-
ture.106 A retrograde type A dissection is associated with
devastating outcomes. TEVAR for aortic dissection is particu-
larly prone to retrograde type A aortic dissection. The risk of
retrograde type A dissection seems to be increased with the
use of proximal balloon dilatation, proximal baremetal stents,
and with rigid non-compliant devices.107 To facilitate the pa-
tient selection process, important anatomical and clinical
features that characterize the aortic dissection pathology
were recently summarized in a new categorisation scheme
(DISSECT), which may be helpful in making the decision of
whether or not to intervene.108
Endovascular repair of ATBAD can be technically chal-
lenging and optimal results can be obtained in high volume
centres with considerable endovascular experience and a
multidisciplinary approach to the treatment of aortic dis-
eases.6,100 Chronic post-TEVAR aortic dilatation may be
observed in patients with persistent and patent FL.87,92,109
Therefore, life long clinical and imaging surveillance are
advised in this situation6 (see also Section 4.).
3.1.1.2.3. Open repair. The aim of OR in the treatment of
ATBAD is to replace the DTA with a graft and excise the
intimal tear, to restore peripheral perfusion and treat or
prevent aortic rupture. Partial cardiopulmonary bypass has
been widely used and hypothermic circulatory arrest has
been adopted for cerebral protection in a subset of patients
who were managed by OR approaches.110e112 There are no
randomized controlled trials available to compare the
different OR techniques and the level of evidence sup-
porting various techniques is low. In patients presenting
with complications such as imminent rupture, rapid
expansion, or malperfusion syndromes, classic OR carries a
signiﬁcant risk of morbidity, including irreversible spinal
injury and post-operative death.110e112 Surgical aortic
fenestration or extra-anatomical bypass has been used for
treating complicated ATBAD, but with the introduction of
minimally invasive techniques, this procedure is only used
as an alternative when endovascular repair fails or is
contraindicated.113
Although the results of OR have improved over the last few
decades,114e117 complications remain high, with in hospital
mortality rates ranging from 25% to 50%.70,71,115,116 Pre-
operative conditions heavily inﬂuence outcomes following
surgical repair.71 Patients older than 70 years with hypoten-
sion or shock have less favourable outcomes, while those,
normotensive at the time of surgery, have better outcomes.71
ReferencesLevel of evidenceClassRecommenda?on 16
In paƟents with complicated acute type B aorƟc dissecƟon, 
endovascular repair with thoracic endograŌing should be the first
line intervenƟon
I C 6,85–89,92–94,96–99,
103,109
Recommenda?on 17
In complicated acute type B aorƟc dissecƟon, endovascular
fenestraƟon should be considered to treat malperfusion
IIa C 73,100–102
Recommenda?on 18
To prevent aorƟc complicaƟons in uncomplicated acute type B aorƟc 
dissecƟon, early thoracic endograŌing may be considered selecƟvely 
IIb B 104
16 V. Riambau et al.
Complications affect 40e80% of patients undergoing open
repair.115 Neurological complications such as paraplegia
(2.3e6.6%), paraparesis (0e3.1%), and stroke (2.7e6.6%)
are associated with the extent and duration of the opera-
tion.71,88,115,116 Beneﬁts from extracorporeal circulation in
the reduction of neurological complications and renal
ischaemia remain controversial.88,114,115 Other complications
include myocardial ischaemia or infarction, respiratory fail-
ure, visceral ischaemia, sepsis, multiorgan failure, and limb
ischaemia.71,88,114e116
3.1.2. Intramural haematoma and penetrating aortic ulcer.
3.1.2.1. Deﬁnition and natural history. Intramural haema-
toma (IMH) is deﬁned as the presence of blood within the
aortic wall without intimal disruption or an identiﬁable
entry point on imaging. IMH may be a precursor to both
classic AD and penetrating aortic ulcer (PAU). It is distin-
guished from AD by the absence of an intimal ﬂap and from
PAU by the absence of any connection with the aortic
lumen.117 Most cases of IMH (50e85%) are located in the
DTA. At least 5e15% of patients admitted with IMH have an
AD. The exact pathophysiology underlying IMH remains
controversial. One theory suggests that IMH is a conse-
quence of rupture of vasa vasorum in the medial layer of
the aortic wall, which then causes a secondary tear into the
aortic lumen. This process is typically associated with hy-
pertension and is initiated by aortic wall infarction. Another
theory suggests that IMH results following an intimal entry
tear, allowing blood from the aortic lumen to enter the
aortic wall. The blood then thromboses within the intimal
layer so that no entry tears can be detected.117,118 Modern
imaging suggests that IMH, PAU, and AD can develop from
each other and, therefore, they are likely to be variants of
the same pathological process. IMH evolves longitudinally
between the medial layers and may progress, regress, or
remain unchanged.117 IMH has identical clinical manifesta-
tions and treatment principles to those of AD. The classiﬁ-
cation of IMH follows that of the Stanford classiﬁcation of
AD. Type A IMH involves the ascending aorta. Type B IMH is
localised in the aortic arch and in the DTA.118
Cross sectional imaging techniques (CTA,MRA) are used to
differentiate between IMH, PAU, and AD. The characteristic
ﬁnding of IMH on axial imaging is a thickening of the aortic
wall greater than 5 mm in an eccentric or concentric pattern.
Mural thrombus has an irregular luminal surface, narrows the
lumen, and does not extend longitudinally as much as IMH.
Discrimination between IMH and acute dissection with a
thrombosed FLmay be difﬁcult. Unenhanced CT acquisition is
crucial for the diagnosis of IMH. A high attenuation crescentic
thickening of the aortic wall, extending in a longitudinal, non-
spiral fashion, is pathognomonic. The aortic lumen is pre-
served and the luminal wall is curvilinear and smooth, as
opposed to a rough, irregular border seen with aortic
atherosclerosis and PAU. IMH is generally a more localised
process than classic AD, which typically propagates along the
entire aorta to the iliac arteries.119
The natural history of type B IMH is similar to that of
ATBAD.7,51 Conservative medical treatment is used for iso-
lated uncomplicated type B IMH.120 Treatment with b-
blockers has a survival rate of 95%, compared with 67% for
those treated without b-blockade.120 IMH, if associated with
PAU, has a signiﬁcantly worse prognosis with a higher risk of
expansion and rupture.51 Regression of acute IMH occurs in
one third, progression in 20%, and up to 40% evolve into AD.7
Indications for treatment in type B IMH are refractory chest
pain, evidenceof increasing size of the expanding haematoma,
aortic rupture, and a progressive pleural effusion.7,51,120
Similarly, there is also considerable controversy regarding
the aetiology of PAU.51 PAU may result from progressive
erosion of atheromatous mural plaque with penetration of
the elastic lamina. PAU may also develop in younger patients
with intimal tears which remain localised and fail to progress
to AD or IMH. PAU is more often present in the DTA and
occurs more often in older patients with arterial hyperten-
sion, hyperlipoproteinaemia, and aortic sclerosis. Compli-
cated PAU involves degeneration towards pseudoaneurysm
formation, dissection, or rupture. Careful imaging is needed
to evaluate both the diameter and depth of PAU.119 Although
the speciﬁc growth rate is unknown, 20e30% of asymp-
tomatic PAUs show evidence of progression over time.119
Symptomatic PAUs have an ominous natural history of
progression and rupture. Urgent repair is commonly rec-
ommended in this setting.119,121 Currently, there is a lack of
data concerning the natural history of patients with
asymptomatic PAU. Progression with pseudoaneurysm for-
mation may occur in 15e50% of cases. The association
between aortic diameter and rupture risk remains unclear.
However, patients with a PAU that initially measures
>20 mm in diameter or >10 mm in depth have a high risk
of disease progression and should be considered candidates
for early endovascular repair.119,121
3.1.2.2. Management. Patients presenting with uncompli-
cated type B IMH are primarily treated by medical therapy
and intensive care monitoring, in line with the management
of AD (see Section 3.1.1.2.1).122
Endovascular repair is currently indicated in symptomatic
or complicated patients or in those with evolution towards
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AD because of a higher risk of peri-operative morbidity and
the risk of rupture.121 Endovascular repair is associated with
lower peri-operativemorbidity andmortality thanOR.123e125
Nevertheless, the role of endovascular repair in patients with
type B IMH is debatable and identifying appropriate in-
dications for treatment is critical. Although the literature
provides no compelling guidelines for treatment, the WC
recommends that treatment of IMH should follow similar
guidelines as for the treatment of AD in the corresponding
segment of the aorta, especially if it is associated with an
evolving PAU, expansion of IMH, intimal tear disruption, or
peri-aortic haematoma or progression to AD.119
Indications and the choice of treatment of PAU are similar
to IMH. High mortality rates have been reported for OR119;
therefore, endovascular repair is the preferred ﬁrst line
treatment.123 According to the largest published series,
speciﬁc aortic diameter, neck length and depth of PAU were
not required for endovascular repair. Indications were pain
and increase of the total aortic diameter at the level of the
PAU.121 In the absence of RCT, the level of evidence for the
treatment of PAU is low.There is currently no evidence based
treatment recommendation available to support treatment
of asymptomatic PAU beyond blood pressure control.
3.1.3. Ruptured aneurysm of the descending thoracic
aorta.
3.1.3.1. Deﬁnition. Most thoracic aortic aneurysms are
either located in the ascending aorta or the DTA, but either
type can extend into the aortic arch. Rupture risk correlates
with aneurysm diameter. Aortic rupture is deﬁned as
disruption of all the layers of the aortic wall (intima, media,
and adventitia). In the acute phase, active extravasation of
blood (as detected by contrast enhanced CTA, MRA, or
echocardiography), is pathognomonic for rupture. Gener-
ally, DTAA rupture is contained by periaortic structures
(pleura, pericardium) or intrathoracic organs (oesophagus,
lungs, heart).
3.1.3.2. Management. Rupture of the DTAA is an acute
condition resulting in a high mortality. Most patients die
before receiving treatment or do not survive treatment.
Survivors are at risk of multisystem organ failure and/or
cerebral/spinal insult. Traditionally, DTAA rupture has been
treated by OR but, in the last few decades, endovascular
repair has emerged as an alternative option in selected
patients. Symptomatic and ruptured DTAAs should be
treated urgently because of the risk of imminent exsan-
guination and death.
3.1.3.2.1. Open repair. Traditionally, ruptured DTAA has
been managed by open repair. A recent meta-analysis of
224 patients with ruptured DTAA demonstrated a 30 day
mortality of 33% for patients treated with OR.126 Major
complications of myocardial infarction, stroke, and para-
plegia have been reported to occur in 11.1%, 10.2%, and
5.5%, respectively. Another recent multicenter, retrospec-
tive review of 69 patients with ruptured DTAA published by
the same authors demonstrated a composite outcome of
death, stroke, or permanent paraplegia in 36.2%.127 These
results were conﬁrmed by a larger study, including data
from the US Nationwide Inpatient Sample data on 559
patients with ruptured DTAA, with a reported mortality rate
of 28.6%.128 These data conﬁrm that OR for ruptured DTAA
is associated with high mortality and morbidity.
3.1.3.2.2. Endovascular repair. TEVAR has emerged as a
less invasive therapeutic option for the management of
ruptured DTAA. No prospective, randomized study has
compared stent grafting versus OR in the treatment of
ruptured DTAA. However, the results of meta-analyses and
multicentre studies suggest lower mortality and complica-
tion rates following TEVAR.126e128
In a recent meta-analysis comparing endovascular repair
and OR for ruptured DTAA, the 30 day mortality was 19%
and 33%, respectively.126 Lower rates of myocardial infarc-
tion (3.5%), stroke (4.1%), and paraplegia (3.1%) were noted
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for endovascular repair. The composite outcome of death,
stroke, and myocardial infarction was 21.7% in the TEVAR
group compared with 36.2% in the OR group (odds ratio
0.49, 95% CI 0.24e0.97, p ¼ .044). By contrast, in the study
using the US Nationwide Inpatient Sample data, TEVAR was
not associated with a signiﬁcantly lower mortality rate
compared with OR (23.4% vs. 28.6%, respectively,
p > .1).128
The need for LSA revascularisation in challenging prox-
imal aortic neck anatomy is controversial, especially in acute
cases. LSA coverage, to achieve a satisfactory proximal seal
during TEVAR for ruptured DTAA, is reported in up to 38%
of cases. LSA revascularisation was not performed in most
of these cases.127,128 Comprehensive data regarding the
rationale for LSA coverage without revascularisation are
unavailable. In one study, subclavian artery bypass was
performed in half of the cases (10/19 covered) before
TEVAR.129 In cases in which the LSA is to be covered, prior
revascularisation of the LSA in the emergency setting is
recommended in patients with a left internal mammary
artery to coronary artery bypass, or in those with a clearly
dominant left vertebral artery. In all other emergency pa-
tients, LSA coverage without revascularisation can be per-
formed49,129 (see also Section 2.4.4.).
In cases with challenging distal thoracic aortic anatomy,
the CA can be selectively covered. Angiography of the su-
perior mesenteric artery (SMA) after balloon occlusion of
the CA can visualize adequate collateral circulation, how-
ever even with proven collateralisation, ischaemic compli-
cations can occur following CA coverage.130 Endovascular
parallel or “periscope” endograft techniques, can poten-
tially be used to maintain perfusion through the coeliac
artery.131 Physician modiﬁed fenestrated endografts have
also been used to maintain perfusion to the CA. The
development of off the shelf fenestrated grafts may provide
new options to treat acute DTA pathology involving visceral
branches (see also Section 3.3.2.3.).
3.1.4. Blunt traumatic thoracic aortic injury.
3.1.4.1. Deﬁnition and diagnostic testing. Blunt traumatic
thoracic aortic injury (TAI) most often occurs after sudden
deceleration as a result of head on or side impact collisions,
usually in high speed motor vehicle accidents or falls from
great heights.
The classic site of TAI is at the aortic isthmus in about
55e90% of patients admitted to hospital alive. Other re-
gions of the thoracic aorta are less often affected.132,133
Trauma to the distal segment of the thoracic aorta can be
associated with injury to the diaphragm and adjacent
compression fractures of the thoracic spine.132
After traumatic brain injury, TAI is the second most
common cause of death in blunt trauma patients. The
morbidity and mortality of this injury are high, causing
sudden death in 80e90% of cases.134 With improved rescue
and rapid detection of TAI, patients who initially survive are
more likely to undergo successful repair.
The damage incurred in TAI can be partial or circumfer-
ential. With more accurate diagnostic tools, the term “mini-
mal aortic injury”, which implies the presence of a small
intimal ﬂap with minimal to no peri-aortic haematoma, has
been introduced to describe a lesion that carries a low risk of
rupture.135 A classiﬁcation scheme for TAI has been pro-
posed: type I (intimal tear), type II (intramural haematoma),
type III (pseudoaneurysm), and type IV (rupture).136
About 2e8% of patients with an initially unrecognized
TAI may develop a chronic post-traumatic pseudoaneur-
ysm.137 There are only a few reports on the natural history
of this type of pseudoaneurysm. The largest series reporting
413 patients was published in 1982.138 Up to 85% under-
went surgical repair, and one third of the remaining patients
died from their untreated lesions within 20 years of the
initial trauma. Other authors report the development of late
symptoms in about 50%, with aneurysmal expansion in
about 20%, and death secondary to aortic rupture in 20%
within 15 years of the injury.139
Clinical presentation ranges from non-speciﬁc symptoms
to thoracic or interscapular pain. Signs of chest wall injury,
pseudo-coarctation syndrome, a systolic murmur, or para-
plegia can be present. The risk assessment for TAI begins
with a high index of suspicion based on the mechanism of
injury. Abdominal injury, thoracic injury, hypotension, and
lack of restraint in motor vehicle accidents have been
identiﬁed as clinical predictors of TAI. The greater the blunt
trauma force the higher the index of suspicion for TAI
should be.140
Initial plain chest X-rays have a signiﬁcant false negative
rate in patients with TAI. Consequently, once aortic
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transection is suspected, computed tomography evaluation
is recommended.141 CTA has replaced angiography as the
ﬁrst line diagnostic test for TAI.142 CTA is quick and repro-
ducible, with a near 100% sensitivity and speciﬁcity in
identifying TAI. In addition, CTA is ideal for evaluating non-
arterial trauma such as brain, spinal, pelvic, splenic, liver,
and kidney damage in patients with multiple injuries. CTA
ﬁndings, associated with TAI, include mediastinal haema-
toma, haemothorax, pseudoaneurysm formation, variation
of aortic contour, and presence of intimal ﬂap and
thrombus. DSA now has a very limited role in TAI
detection.142
With the increasing use of TEVAR, IVUS has been advo-
cated as having an important role in the evaluation of
selected patients with suspected TAI.143 Most of the patients
who undergo TEVAR for TAI are young.144,145 These patients
have a healthy and elastic aortic wall, with increased aortic
pulsatile compliance. Aortic diameter varies in these patients
by 10% (up to 18%) between systole and diastole.145 In
contrast to CTA, IVUS permits a dynamic real time evaluation
of aortic diameters during the cardiac cycle. Furthermore,
IVUS can easily detect the origin of side branches, allowing
less use of contrast with DSA. Once the stent graft is
deployed, IVUS can be used to evaluate adequate expansion
of the stent, excluding infolding complications.
TOE has a limited role and low sensitivity in routine
screening for TAI and should not be performed at the
expense of prompt evaluation of other coexisting injuries.
However, DSA and TOE might be used together when CTA is
not available or is equivocal.143 TOE can also be used intra-
operatively to monitor myocardial function and ﬂuid man-
agement. In addition, TOE has gained an important role in
the delivery of stent grafts in TEVAR143 (see also Section
2.3.4.).
3.1.4.2. Management. The appropriate timing of any oper-
ation in patients with TAI remains controversial. In 1997, the
American Association for the Surgery of Trauma (AAST) pub-
lished amulticentre study reporting that about 9% of patients
reaching the hospital haemodynamically stable, progressed to
free rupture. The majority of these ruptures occurred within
24 hours.146 For this reason, immediate treatment of TAI was
considered the standard of care for many years.
More recent studies147,148 have shown a reduction in
paralysis and mortality with delayed treatment. In 2008, a
prospective, observational, multicentre study by the AAST
demonstrated similar complication rates, but a signiﬁcantly
higher mortality in patients who underwent early repair
when compared with delayed repair. The study concluded
that patients with TAI and associated major injuries are
more likely to beneﬁt from delayed intervention.149
This conclusion is consistent with an extensive review of
the literature150 including 139 studies and 7,768 patients,
which did not show a signiﬁcant difference in mortality
between early (within 24 hours) and delayed (after
24 hours) repair, suggesting that repair can be delayed if
other extensive injuries require stabilisation. These con-
clusions are consistent with the guidelines of The Society of
Vascular Surgery, which suggest urgent repair (within
24 hours) barring other serious concomitant non-aortic
injuries, or repair immediately after other injuries have
been treated but prior to hospital discharge.151
The type of aortic injury is also a determining factor in
the timing of intervention. Patients with a 15 mm or larger
arch haematoma were signiﬁcantly more likely to die from
TAI than those with a smaller haematoma. By contrast,
minimal aortic injuries that present with an intimal tear and
occur in 10% of patients with TAI may be managed
expectantly with serial imaging for surveillance.135,151
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3.1.4.2.1. Open repair. OR of a TAI at the classic isthmus
location requires exposure of the aorta through a left fourth
interspace thoracotomy with single right lung ventilation to
improve surgical exposure. The aorta is clamped at the
origin of the LSA and distal to the vessel injury. Until the
mid-1980s, most of these procedures were completed with
an expeditious clamp-and-sew technique. Although there
are isolated reports of reasonable outcomes,152 meta-
analyses of this technique have reported a mortality of
16e31% and a paraplegia rate of 5e19%.147,148,153
Various methods of distal aortic perfusion have been used
to protect the spinal cord. Early techniques used heparin-
bonded intraluminal shunts (passive perfusion).153 Meta-
analyses and large-cohort studies of active versus passive
perfusion showed a decrease in the rate of post-operative
paraplegia from 19% to 3% and a mortality reduction from
30% to 12% in favour of active perfusion with partial car-
diopulmonary bypass154 (see also Section 2.4.2.).
Optimal peri-operative patient management with a skilled
trauma team is mandatory to establish the correct timing and
treatment priorities. Aggressive ﬂuid administration that may
exacerbate bleeding, coagulopathy, and rupture should be
avoided. MAP should not exceed 80 mm Hg.136 Hypotension
(systolic blood pressure 90 mm Hg), and peri-aortic hae-
matoma size (15 mm) were found to be independent risk
factors for early mortality in patients with TAI.144
In patients suffering severe brain injury with elevated
intracranial pressure and haemorrhage or signiﬁcant lung
injury, delayed repair of TAI is preferable to avoid further
brain or respiratory deterioration.133
3.1.4.2.2. Endovascular repair. The ﬁrst TEVAR procedure
for a post-traumatic aortic pseudoaneurysm was performed
in 1987 by Nicolai Volodos in Ukraine.155 Since then, TEVAR
has become the “ﬁrst choice treatment” for TAI for many
authors because of good early and late re-
sults.126,129,136,147,149,152,156e161 Data extracted from the
Nationwide Inpatient Sample in 2006 showed a signiﬁcant
change from OR to TEVAR in the USA.162 A recent non-
systematic review of the literature159 identiﬁed 62 retro-
spective reviews or studies and six meta-analyses. A sub-
group analysis of these papers showed that the TEVAR
population was older, whereas patients in the OR group were
more often unstable. Compared to OR, TEVAR showed a
signiﬁcantly reducedmortality (9.7% vs. 27.7%; p< .001) and
a trend towards reduced paralysis (0.4% vs. 2.9%). OR of TAI
was associated with a reduced stroke rate (0.4% vs. 2.3%).
Combining these neurological complications (paralysis and
stroke), the complication rate was comparable between the
two groups. Overall, the endoleak incidence was 5.2% (type I
proximal in almost all cases).There was a 1%migration rate in
this cohort and stent collapse occurred in 2.5% of cases with
an associated mortality of 12.9%. Similar advantages were
found in a systematic review in terms of survival and a
decreased incidence of paraplegia with TEVAR, when
compared with OR. This review reported an early endoleak
rate of 4.2% and a stent collapse rate of 1.2%. The latter
complication was fatal in 30% of cases.160
Most TAI occur in young patients, who are more likely to
have acute curvature of the aortic arch. This anatomical
variant may limit the optimal apposition of the stent graft
to the inner aortic curvature, leading to “bird beaking” and
an increased risk of endoleak and stent collapse.163 The
average diameter of the thoracic aorta, proximal and distal
to the rupture site, is 19 mm in patients with trauma.
Excessive oversizing (>20%) has been associated with an
increased risk of device collapse.163 With respect to pre-
operative CTA measurements, stent grafts should be
oversized by about 10%. More aggressive oversizing may
be applied in gravely hypotensive patients, but not
exceeding 20%. Hypotension may lead to inadvertent
undersizing of the stent graft with a consequent increased
risk of migration, endoleak, and/or graft collapse once
resuscitation is fully achieved.164 Where possible, delayed
TEVAR may allow complete resuscitation. In these cases,
serial CTA imaging can provide more reliable data
regarding the actual aortic measurements for stent graft
sizing.164
The necessity of LSA coverage during TEVAR for TAI was
reported in 30% of cases in recent reviews.150,160 As in
other pathological situations, in the emergency setting LSA
revascularisation is recommended in patients with left in-
ternal mammary artery to coronary artery bypass, and
when the presence of a dominant left vertebral artery as-
sures a better posterior cerebral perfusion compared with
the right49,129 (see also Sections 2.4.2. and 3.1.3.2.2.).
A separate consideration should be applied to chronic
post-traumatic pseudoaneurysms, which have different
anatomical characteristics from degenerative aneurysms, in
that they are typically localised, calciﬁed saccular lesions
located just distal to the LSA, making them attractive targets
for endovascular repair.165
The indications for late surgical intervention after aortic
injury are not the same as those for other types of DTAA
(see also Section 3.3.).
Follow up strategies after TEVAR for TAI deserve a special
mention. A combination of multi-view chest X-rays and
MRA, rather than CTA, may be considered166 (see also
Section 4.).
3.2. Chronic type B aortic dissections
3.2.1. Deﬁnition and natural history. Historically, TBAD is
deﬁned as “chronic” when 14 days have elapsed from the
acute event. This temporal classiﬁcation is based on the fact
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that 70% of deaths from aortic dissection occur within 2
weeks of onset.167 The risk of death following dissection
remains high during the ﬁrst 3 months and, in recent years,
it has been suggested that a separate category of dissection,
termed sub-acute (between 2 weeks and 3 months of the
initial dissection), should be included. Additionally, the po-
tential for endograft-stimulated aortic remodelling within
this time period is higher.98
In general, chronic type B aortic dissection (CTBAD) also
includes patients with a residual TBAD after repair of a type A
dissection (De Bakey type I dissection).168 Aortic related
complications may occur in 20e50% of patients with
CTBAD.169 Overall, it is estimated that approximately 20e40%
of patients with CTBAD develop enlargement of the FL that
warrants treatment and approximately 25% of DTAA or TAAA
are associated with AD.170 Aside from aneurysmal degenera-
tion, aortic related complications include recurrent dissection,
retrograde dissection, and rupture of the FL. The expansion
rate of the chronically dissected aorta is not well known but
ranges between 1 and 7 mm per year.171 Hypertension, an
aortic diameter of 40 mm or more in the acute phase, chronic
obstructive pulmonary disease, and patency of the FL have
been recognized as risk factors for late aneurysmal degener-
ation.169 In addition, the presence of an entry tear larger than
10 mm in diameter or located in the arch or proximal DTA has
been recognized as a predictor of late mortality and the
consequent need for aortic repair.168 Moreover, in patients
treated for type A dissection with a patent distal FL, a large
area of the FL (>70% of the total aortic area) is considered to
be a predictor of aneurysmal degeneration.202
Conversely, FL thrombosis has been associated with
a slower growth rate.172,173 Interestingly, partial distal FL
thrombosis has been shown to be an independent
predictor of mortality after hospital discharge in patients
with a CTBAD.174 The responsible mechanism may be
increased FL pressure resulting from a large entry tear
without outﬂow.175 In addition, an increased risk of rupture
in aneurysms resulting from AD has been observed when
compared with degenerative aneurysms,176 although there
is insufﬁcient evidence to support treatment at a lower
diameter.
Long-term survival after uncomplicated type B dissec-
tions remains relatively poor. An analysis of the IRAD
database has shown that late mortality is high in patients
discharged from the hospital after ATBAD, approaching 25%
within 3 years.85 Most deaths in patients with CTBAD are
related to comorbid conditions.92
3.2.2. Management. Aggressive medical therapy and close
surveillance of the aorta remains the cornerstone of
management to reduce the risk of late mortality and
aortic complications. In a non-randomized, observational
study, improved survival was shown in patients treated
with b-blockers in the chronic phase of AD. This study
reported an 80% freedom from aortic events at a mean
of 4.2 years in patients on b-blockers, in comparison with
47% freedom from aortic events in patients treated with
other antihypertensive agents. The efﬁcacy of other
antihypertensive drugs has not been speciﬁcally demon-
strated in patients with CTBAD, although these drugs
have a role in maintaining appropriate blood pressure
(systolic below 130 mm Hg and diastolic below 85 mm
Hg).80
Several studies have suggested that 40e70% of late
deaths in patients with CTBAD are caused by comorbid
diseases, mainly heart disease and stroke,177 emphasizing
that cardiovascular risk factors should be thoroughly
assessed and treated in this group. Interestingly, cigarette
smoking does not seem to affect aortic expansion and
rupture rates,178 although its detrimental role on cardio-
vascular risk is well established.
3.2.2.1. Indications for repair. The main goal of aortic repair
in patients with CTBAD is to avoid aneurysmal degeneration
and rupture of the aorta. The presence of malperfusion also
mandates repair. Clinical and radiological factors may indi-
cate the need for treatment.
New onset symptoms of AAS, such as lumbar back pain not
caused by other conditions, hypotension, a new peripheral
pulse deﬁcit or blood pressure differential, new focal neuro-
logical deﬁcit, or signs of end-organ malperfusion in patients
with chronic dissection, mandate immediate evaluation to
exclude rupture or progression of the dissection.171
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In asymptomatic patients, the maximum aneurysm
diameter remains the most important indicator for treat-
ment. A large aortic diameter is associated with increased
rupture risk, and several authors have shown that an aortic
diameter between 50 and 60 mm is associated with rupture
in almost 20% of cases.92,97,167,179 It should be acknowl-
edged that there is a paucity of literature describing the
aortic rupture risk in relation to aortic diameters in patients
with CTBAD.
3.2.2.2. Open repair. Despite the lack of data regarding
comparison between open and endovascular repair, OR
remains the standard treatment in low surgical risk patients
with CTBAD because of an improvement in surgical results
over the last 20 years.41,54,180 It should be noted that
although several authors speciﬁcally report low surgical risk
as a prerequisite for OR, the deﬁnition of surgical risk in
thoracic aortic surgery is difﬁcult. The most commonly used
cardiac surgery risk models (European System for Cardiac
Operative Risk Evaluation - EuroSCORE, Department of
Veterans Affairs Continuous Improvement in Cardiac Sur-
gery Program - CICSP) report contradictory results when
applied to thoracic aortic surgery. In particular, a Japanese
study showed that the logistic EuroSCORE was able to
reliably predict in hospital mortality in 327 consecutive
thoracic aortic procedures.181 Conversely, an American
study reported that both the EuroSCORE and the CICSP
greatly overestimated operative mortality rates in a series
of 100 patients treated in a tertiary centre182 (see also
Section 3.4.2.2.).
The mainstays of surgical repair of chronic dissection
are similar to those of thoracic aortic aneurysms or
TAAA. Patients with chronic dissections typically require
a more complex operative repair because of the presence
of the intimal ﬂap. This can lead to longer operation
times with increased risk of bleeding, SCI, and renal
failure.183
Aneurysms caused by chronic dissection are generally
more extensive than degenerative aneurysms and also
develop in younger patients. Several extracorporeal circu-
lation methods and adjunctive measures for end organ and
spinal cord protection have been described. Differing
opinions exist regarding the use of these adjunctive
methods (see also Section 2.4.).
In early reports on OR treatment, chronic dissection was
a risk factor for paraplegia with an incidence approaching
30e35%.184 Indeed, these patients seem to have a different
pre-operative risk proﬁle compared with those with
degenerative aneurysms, as they are more likely to present
in an emergency/urgent fashion, have a connective tissue
disorder, and be Crawford type I and II TAAA.183 With the
introduction of surgical adjuncts, the negative predictive
value of chronic dissection on paraplegia has been reduced
and, at present, is not considered a predictor of SCI in
thoraco-abdominal aneurysm repair185 (see also Sections
2.4. and 3.4.2.2.).
In numerous contemporary, single centre series of pa-
tients with complex aortic pathologies treated by OR, re-
ported mortality rates range from 6% to 11%, with
paraplegia/paraparesis being reported in 3.6e
12%.41,180,183e185 In contrast to high volume centres, na-
tional registries and community based outcome analyses
suggest that the mortality for the overall treatment of dis-
sections by OR techniques is signiﬁcantly higher and may
exceed 20%.186 These data reinforce the recommendation
for centralisation of OR for chronic type B dissection, as well
as for TAAA (see also Section 3.4.2.2.).
Level of evidenceClassRecommenda?on 33 References
In paƟents with chronic aorƟc dissecƟon and acute aorƟc symptoms,
emergency repair should be considered if malperfusion, rupture, or
progression of dissecƟon is confirmed on imaging 
IIa C 171
Recommenda?on 34a 
In paƟents with chronic aorƟc dissecƟon, a descending thoracic aorƟc
diameter between 56 and 59 mm may be considered as an indicaƟon
for treatment in paƟents at reasonable surgical risk 
IIb C 167,176
Recommenda?on 34b 
In paƟents with chronic aorƟc dissecƟon, a descending thoracic aorƟc
diameter greater than 60 mm should be considered as an indicaƟon
for treatment in paƟents at reasonable surgical risk 
IIa C 97,167,176
Recommenda?on 35 
In paƟents with chronic aorƟc dissecƟon and thoraco-abdominal
extension, an aorƟc diameter greater than 60 mm should be
considered as an indicaƟon for treatment in paƟents at reasonable
surgical risk 
IIa C 167,176
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3.2.2.3. Endovascular repair. Since 1999, endovascular repair
has been used increasingly in the treatment of CTBAD.90 The
goal of endovascular repair is to seal the proximal entry tear,
facilitate aortic remodelling to achieve thrombosis of the FL,
and thereby reduce the likelihood of aortic rupture in themid-
to long-term. The technique of endovascular repair involves
placement of a stent graft over the primary entry tear in the
DTA, usually via a trans-femoral route.
There are limited data comparing endovascular with OR for
CTBAD. A published series of 24 patients undergoing repair of
chronic dissection, showed mortality in the endovascular
groupof 0% comparedwith 33% in the open group.90National
registry data support an improved long-term outcome in pa-
tients undergoing endovascular repair of AD in comparison
with OR.186 More recently, larger series have supported the
concept that endovascular repair of CTBAD is associated with
lower morbidity. A recent systematic review of TEVAR for
chronic AD detailed 567 cases. In this review, the early (30 day
or in hospital) mortality was 3.2%, the incidence of stroke
0.82%, and SCI occurred in 0.43%.187
Endovascular repair of chronic dissection appears to be
associated with lower mortality and morbidity rates than
for AD, a difference attributable to the high incidence of
emergency procedures in the acute setting. There is now a
reasonably robust body of evidence to support the asser-
tion that endovascular repair of chronic dissections may be
achieved with mortality rates below 5% and a low inci-
dence of neurological complications, even in complicated
cases.88,188
In the previously mentioned systematic review, the me-
dian length of follow up was 26 months. The all cause
mortality rate was 9.2%. The mid-term aortic related mor-
tality from those studies was 4.2%. The most common
delayed complication was the development of aneurysms of
the distal aorta or continuation of FL perfusion with aneu-
rysmal dilatation (7.8%). Delayed aortic rupture was re-
ported in 3.0%. No studies reported whether rupture
occurred within or distal to the stented segment, or
following persistent FL perfusion. Rates of complete FL
thrombosis ranged from 38% to 100% (median 86%) in
studies with a median follow up of 17 months. Studies
reporting mid-term follow up of aortic morphology
observed a reduction of the FL diameter in 79% of patients,
FL expansion occurred in 15%, and TL expansion in 66%.
Data from this review should be interpreted carefully
because of the poor quality of the studies included.187
The advent of thoracic endografting has opened up a
potential therapeutic avenue for patients with uncompli-
cated sub-acute type B thoracic dissection. Without inter-
ventional therapy, a substantial proportion of these patients
will go on to develop a large aneurysmal chronic dissection
that may require therapy.169 Treatment of chronic dissec-
tions is difﬁcult and from an endovascular perspective, re-
quires extensive thoracic coverage because of poor aortic
plasticity. It has been hypothesized that a subset of patients
with sub-acute dissection (between 2 and 12 weeks after
the index process), could be identiﬁed on the basis of
morphological and physiological characteristics that pre-
dispose to formation of aneurysmal chronic dissection.
These patients might then be preferentially treated in the
sub-acute phase.
Patients with sub-acute TBAD have a low endovascular
repair mortality rate and a signiﬁcantly greater aortic plas-
ticity than patients with chronic dissections. Although
attractive as a hypothesis, the morphological features that
predict late expansion are not fully deﬁned189 and further
research is needed in this ﬁeld.
The INSTEAD trial randomized patients with sub-acute
and chronic dissections to early endovascular repair or
best medical management and surveillance. Although
aortic remodelling was greater in the endovascular group,
there were no statistically signiﬁcant differences between
the groups regarding 2 year mortality. Later follow up re-
sults have been published recently.190 It has been
demonstrated that TEVAR, in addition to optimal medical
treatment, was associated with improved 5 year aorta
speciﬁc survival and delayed disease progression. The au-
thors concluded that in cases of stable CTBAD with suitable
anatomy, preemptive TEVAR should be considered to
improve late outcomes. A proportion of patients with sub-
acute dissection may, therefore, beneﬁt from early endo-
vascular repair,190 especially in those at risk of further
aortic complications.168,169,172e174,189
One issue that requires clariﬁcation is whether endo-
vascular repair is effective in reducing aortic related death
in the mid- to long-term. OR series demonstrate a high early
aortic related mortality, but effective prevention of aortic
related death in the long term.180 Data regarding preven-
tion of aortic related death are less robust for endovascular
techniques. A series of 76 patients reported 12 late deaths.
Only one was deﬁned as aortic related (rupture of an un-
treated ascending dissection).191
ClassRecommenda?on 36 Level of evidence References
Open repair of aneurysmal or symptomaƟc chronic type B aorƟc
dissecƟon in paƟents with low surgical risk should be considered in
dedicated centres with low complicaƟon rates 
IIa C 41,180
Recommenda?on 37 
In paƟents with chronic type B dissecƟon undergoing operaƟve repair,
intra-procedural cerebrospinal fluid drainage, leŌ heart bypass, and
moderate hypothermia should be considered to reduce procedural
mortality and spinal cord injury. 
IIa C 41,183
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The ability of the aorta to remodel after endovascular
repair of acute and chronic dissections has been studied.
Following coverage of the primary entry tear in ATBAD,
there is rapid aortic remodelling with an increase in
diameter of the TL and a reduction in FL diameter.91,192
By contrast, in chronic dissections, there is less aortic
remodelling and the integrity of the endovascular repair
is determined by the ability of the endovascular proce-
dure to induce FL thrombosis. In treating chronic dis-
sections, it has been shown that FL thrombosis occurs
more often in patients with limited dissection and that FL
thrombosis occurs more effectively in the stented part of
the DTA.191
These ﬁndings suggest that the extent of coverage of the
DTA is directly related to the extent of FL thrombosis.
Although SCI rates after TEVAR for chronic dissection are
lower than those after TEVAR for thoracic aneurysms,
increased aortic coverage may increase the risk of SCI. To
reduce SCI rates, spinal cord perfusion should be main-
tained whenever possible through collateral channels,
especially from the LSA. Irrespective of the extent of aortic
coverage, the dissected portion of the aorta below the
diaphragm remains untreated, and there is evidence to
suggest that this region may dilate over time.91 The role of
bare stents in the treatment of chronic dissection, and the
effect that these stents have on aortic remodeling, remain
undeﬁned at the present time.99
The available literature regarding TEVAR for chronic
dissection in patients with MFS is sparse.193 Early technical
feasibility has been demonstrated, but long-term outcomes
remain uncertain. The fragility of the aorta in MFS and other
associated conditions poses a problem for proximal aortic
ﬁxation and may lead to the development of complications
(see also Section 3.7.1.1.).
Recently, new endovascular techniques have been tested
to induce FL thrombosis in chronic CTBAD. Despite the
feasibility and the early usefulness that have been
demonstrated in selected patients in highly experienced
centres, it is too early for widespread adoption and for a
general recommendation statement.194
3.3. Descending thoracic aortic aneurysms
3.3.1. Deﬁnition and natural history. Descending thoracic
aortic aneurysms (DTAA) are deﬁned as any aortic dilatation
with at least a 50% increase in diameter located in any
segment of the aorta between the LSA origin and the dia-
phragm (see also Section 2.1. for normal values). Histo-
pathologically, it is characterized by medial degeneration,
with disruption and loss of elastic ﬁbres and increased
deposition of proteoglycans, with or without
atherosclerosis.
At any given increased size of various aortic segments,
the expansion rate is greatest in the DTA. There are many
other factors that affect the expansion rate apart from
diameter and anatomical location including smoking,
intraluminal thrombus, chronic obstructive pulmonary dis-
ease (COPD), and vascular disease.195 Once diagnosed, the
prognosis of large degenerative aneurysms (more than
60 mm in diameter) is poor if not treated, with a 3 year
survival of approximately 20%.196
3.3.2. Management. The rate of expansion is important in
deciding the frequency of surveillance in DTAA. Risk factors
for rupture include maximum aneurysm diameter, age,
gender, active smoking status, diastolic hypertension, and
aneurysm related pain.9,176,196,197
3.3.2.1. Indications for repair. An initial diameter of 60 mm
carries an annual risk of rupture of 10%. For DTAA, there is a
threshold of 70 mm at which the risk of rupture suddenly
escalates.127 Intervention in aneurysms below 55 mm may
not afford a survival beneﬁt, although a randomized
controlled trial is necessary to evaluate the possible beneﬁt
of repair in the small aneurysm group.9 This threshold can
be reduced to 50e55 mm for women or in the setting of
connective tissue disorders (see also Section 3.7.1.).54,88
3.3.2.2. Open repair. Indications for OR of a DTAA are
limited to ﬁt patients (see also Section 3.3.2.3.) unsuitable
for TEVAR such as those with:
1) Absence of adequate arterial access197 or a
contraindication to aortic/iliac conduit graft placement
(presence of hostile abdomen, severe aorto-iliac
disease). The use of an aortic/iliac sidearm graft is
required in approximately 15% of cases.54
2) Absence of proximal or distal landing zones.
3) DTA associated with a connective tissue disorder such
as MFS, or DTA in young, healthy patients without
major contraindications for OR.54,88
4) Prohibitively high risk of neurological deﬁcit post-TEVAR
caused by full extent DTAA in patients with previous
ReferencesLevel of evidenceClassRecommenda?on 38
In paƟents with moderate to high surgical risk or with contraindicaƟons
to open repair, endovascular repair of complicated chronic type B
aorƟc dissecƟons should be considered in dedicated centres 
IIa C 187
Recommenda?on 39 
In paƟents at risk of further aorƟc complicaƟons with suitable anatomy
for endograŌing, endovascular repair of uncomplicated chronic type B
aorƟc dissecƟons should be considered in the sub-acute phase, in
dedicated centres 
IIa B 190
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abdominal aortic surgery, reducing pelvic circulation and
occlusion of the lumbar arteries.45,198e200
5) Symptoms related to compression by a large DTAA of
adjacent structures such as the thoracic vertebral bodies
(chronic pain syndrome), trachea or left mainstem
bronchus (dyspnea), or oesophagus (dysphagia).201
The extension and the location of the disease affect the
surgical decision making process in terms of type of incision
and use of peri-operative adjunctive measures. A classiﬁ-
cation has been proposed to deﬁne the risk of SCI during
DTAA repair. Such a classiﬁcation distinguishes three types
of DTAA: type A, which involves the proximal DTA and ends
at the level of T6; type B, which involves the distal portion
of the DTA starting at the level of T6; and type C, which
affects the entire DTA202 (see Fig. 2).
Pre-operative planning should include a CTA or MRA eval-
uation of the spinal cord circulation including lower lumbar
and pelvic arteries, which play a major role in spinal cord
blood supply in 16% and 8% of cases, respectively.198,199
The pre-operative assessments of cardiac, pulmonary,
and renal function, as well as carotid and peripheral arterial
occlusive disease are essential to minimize the risks of
mortality and morbidity associated with DTAA repair.
Additional studies such as echocardiography, cardiac cath-
eterisation, and, in selected cases, Holter 24-hour electro-
cardiography monitoring, are usually requested for patients
with a history of coronary or valvular heart disease.
Symptomatic coronary artery disease (CAD) is always
treated aggressively before aortic surgery. The management
of asymptomatic patients with CAD remains controversial
given recent evidence suggesting a more conservative
approach203 compared with older data.204 In the evaluation
of such cases, the extent of the planned procedure and the
severity of the CAD determine the pre-operative strategy.
A history of smoking and the presence of COPD increase
the risk of post-operative respiratory failure. Pulmonary
function tests and arterial blood gas analyses should be
performed in all patients.205
The risk of post-operative renal failure is higher in pa-
tients with impaired renal function. This scenario can be
successfully managed by pre-operative hydration and
adequate renal perfusion during the peri- and post-
operative period.206
There is robust evidence showing that the risk of SCI,
mesenteric and renal ischaemia is related to the duration of
cross clamping, and that cross clamp time represents the
most important predictor of post-operative neurological
deﬁcit.28,31,114,206 Methods of extracorporeal circulation
include LHB and cardiocirculatory arrest. This more
aggressive approach can prove useful in the presence of
rupture or when proximal aortic clamping entails a high
risk.207 However, in a retrospective analysis of 387
consecutive DTAAs, no signiﬁcant paraplegia risk reduction
was found by applying LHB in DTAA OR114 (see also Section
2.4.2 for prevention of spinal cord ischaemia).
Outcomes following elective OR for DTAA have improved
over the past 25 years in some high volume cen-
tres.114,208,209 However, these acceptable results were not
corroborated in an American National Inpatient Sample
administrative database, presumably reﬂecting results ach-
ieved outside centres of excellence. Mortality rates in
elective and emergency cases were 10% and 45%, respec-
tively. Furthermore, spinal cord ischaemia has also been
reported in the range of 11e15%.210
3.3.2.3. Endovascular repair. Evidence comparing OR and
TEVAR in the treatment of DTAAs relies on systematic re-
views and meta-analysis of retrospective series and non-
randomized controlled or population based studies.211e215
The available results decisively favour a less invasive
approach in terms of mortality, morbidity, and length of
hospital stay. These results were, however, tempered by
several less impressive results, such as long-term survival.213
In a meta-analysis of 17 studies with 517 elective pa-
tients treated by OR and 538 patients treated by TEVAR,
the endovascular cohort demonstrated a lower 30 day
mortality rate (5.57% vs. 16.5%). TEVAR was also associated
Figure 2. Classiﬁcation of DTAA according to the extension.202
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with a signiﬁcant reduction in peri-operative mortality
(pooled OR [odds ratio] 0.36, 95% CI 0.228e0.578;
p < .0001). Major neurological complications occurred in
26 TEVAR patients (5.4%) and 67 OR patients (14%).
Endovascular repair was associated with a reduced risk of
paraplegia (pooled OR [odds ratio] 0.33, 95% CI 0.18e0.63,
p < .0007). The risk of stroke was not affected by TEVAR
(pooled OR [odds ratio] 0.77, 95% CI 0.38e1.59, p ¼ .48).
TEVAR had no impact on the major re-intervention rate at
48 months (pooled OR [odds ratio] 0.91, 95% CI 0.610e
1.619), which was 8.4% versus 7% for OR and TEVAR,
respectively.212
SCI can occur after TEVAR. A recent observational study
on 424 DTAA treated by TEVAR reported 12 cases of SCI
(2.8%).216 Several reports conﬁrm that speciﬁc anatomical
conditions may represent potential risk factors for post-
operative SCI. These include planned coverage of the
thoracic aorta over more than 200 mm or involving the level
T8-T12, previous abdominal aortic surgery with ligation of
lumbar arteries, an occluded hypogastric artery, and, in the
emergency setting the need for LSA coverage not amenable
to revascularisation. Chronic renal failure and a peri-
operative MAP lower than 70 mm Hg may also play a role
in the development of SCI.216e218 In the presence of one or
more such risk factors, CSF drainage should be performed
to reduce the risk of SCI post TEVAR (see also Section
2.4.3.).
Intentional coverage of the LSA during TEVAR to provide
adequate proximal sealing and ﬁxation has been reported in
10e50% of cases. A robust body of evidence, based on
observational studies, shows that this increases the risk of
stroke, SCI, and upper limb ischaemia.44e50 An additional
meta-analysis reported an almost doubled rate of cerebro-
vascular events (4.7% vs. 2.7%, OR [odds ratio] 2.28, 95% CI
1.24e4.09) and SCI (2.8% vs. 2.3%, OR [odds ratio] 2.39,
95% CI 1.30e4.39, p ¼ .005), when the LSA was covered219
(see also Sections 2.4.3. and 2.4.4.).
An inadequate distal landing zone of less than 15mm length
and a proximal neck diameter exceeding 40 mm are contra-
indications for TEVAR with currently available devices.215,220
These anatomical limitations occurred more commonly than
the rate of 4.4% previously reported in amulticentre review of
TEVAR.220 In spite of these data, safe coverage of the CA has
been described to achieve acceptable distal sealing and ﬁxa-
tion.221 CTA is suitable to assess anatomical details of the distal
DTA and the proximal abdominal aorta; however, selective
ReferencesLevel of evidenceClassRecommenda?on 40
Computed tomographic angiography or magneƟc resonance
angiography should be performed for paƟents planned for descending
thoracic aorƟc repair, to define the extent of the disease and to
idenƟfy the potenƟal risk of the procedure related to the main
intercostal arteries 
I C 198,199
Recommenda?on 41 
In candidates for open surgical repair of descending thoracic aorƟc
aneurysms with a past medical history of coronary artery disease,
addiƟonal diagnosƟc invesƟgaƟons should be considered to define the
severity of the underlying heart disease 
IIa C 204
Recommenda?on 42 
RevascularisaƟon of symptomaƟc or severe asymptomaƟc coronary
artery disease should be considered before open descending thoracic 
aorta surgery 
IIa C 203
Recommenda?on 43 
StraƟficaƟon of peri-operaƟve risk associated with pulmonary, renal,
and cerebrovascular studies should be considered 
IIa C 31,205,206
Recommenda?on 44a 
Open repair may be considered for fit paƟents, with a descending
thoracic aorta between 56 and 59 mm in diameter, who are unsuitable
for endovascular repair 
IIb C 88,197
Recommenda?on 44b 
Open repair should be considered for fit paƟents, with a descending
thoracic aorta exceeding 60 mm in diameter, who are unsuitable for
endovascular repair 
IIa C 88,197
Recommenda?on 45 
To reduce the incidence of postoperaƟve paraplegia, leŌ heart bypass is
not recommended for paƟents undergoing open repair for descending
thoracic aneurysm
III C 114
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angiography of the CA and SMA remains themost reliable test
to predict the role of potential collateral circulation following
CA coverage during TEVAR.221
Contraindications to CA coverage include the presence of
a common coeliaco-mesenteric trunk, the absence of
adequate angiographic evidence of collateral circulation,
poor portal vein perfusion, and any previous conventional
or endovascular procedure that may have compromised the
collateral circulation.221
An alternative solution to CA coverage in certain situa-
tions is a scallop-designed endograft or the use of a “snorkel
or chimney technique”. The use of these techniques is
promising, although supported by only few data.
3.4. Thoraco-abdominal aortic aneurysms
3.4.1. Deﬁnition. Crawford ﬁrst described the extent of
thoraco-abdominal aortic aneurysms (TAAA) and his classiﬁ-
cation has found general acceptance. Type I TAAAs start at the
level of the LSA, or at least proximal to the level of the sixth
vertebra (T6) and affect the entire DTA, involve the visceral
arteries and end at the renal arteries.Theaneurysmcan involve
the origin of the LSA or even involve the distal aortic arch.Type
II TAAAs start at the same level as a type I, but involve the DTA
and the entire abdominal aorta. In many patients, especially
those suffering from connective tissue diseases and post-
dissection aneurysms, the iliac arteries are aneurysmal as
well. Type III TAAAs start more distal than type II aneurysms,
usually at the level of T6, and extend distally as in a type II.Type
IV TAAAs start at the level of the diaphragm and involve the
entire abdominal aorta, with or without extension to the iliac
arteries. A type V TAAA starts below the sixth intercostal space
and tapers just above the renal arteries (Fig. 3).222
Using this classiﬁcation, an international consensus has
been achieved on describing the extent of aneurysmal
disease. Both in open and endovascular repair, this classi-
ﬁcation provides an indication of the extent of the proce-
dure, the likely technical challenges involved in any repair,
and the potential post-operative risks. For example, a type
IV TAAA can technically be performed by laparotomy only,
whereas all the other types require a thoraco-abdominal
incision, (partial) incision of the diaphragm, and tempo-
rary collapse of the left lung, reﬂecting the potential for
substantial differences in surgically induced trauma be-
tween these two exposures. Furthermore, the ﬁve types are
each associated with different end organ complications
such as paraplegia, renal failure, and visceral ischaemia.
3.4.2. Management.
3.4.2.1. Indications for repair. It is extremely important to
assess the risk of any intervention against the risk of
rupture. Extensive pre-operative risk analysis is required as
an essential part of the decision making process, especially
in patients with comorbidities. General consensus exists
regarding surgical repair of TAAA for low to moderate sur-
gical risk patients with TAAA larger than 60 mm (less for
patients with connective tissue disorders), rapid growth
(>10 mm/year), or with symptoms.112,223
Figure 3. Crawford TAAA classiﬁcation modiﬁed by Saﬁ.222
Level of evidenceClassRecommenda?on 46a References
In fit and unfit paƟents with favourable anatomy, endovascular repair
may be considered for descending thoracic aorta aneurysms between
56 and 59 mm diameter
IIb B 88,211–215
Recommenda?on 46b 
In fit and unfit paƟents with favourable anatomy, endovascular repair
should be considered for descending thoracic aorta aneurysms >60
mm diameter 
IIa B 88,211–215
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3.4.2.2. Open repair. Open TAAA repair is a major aortic
intervention and is associated with post-operative compli-
cations including myocardial infarction, respiratory failure,
renal insufﬁciency, stroke, paraplegia, and death. To esti-
mate the risks of OR, pre-operative cardiopulmonary and
renal assessment is required. Patients with degenerative
TAAA are usually older than patients with post-dissection or
connective tissue disease aneurysms. A substantial number
(34e40%) will suffer from CAD, and compromised cardiac
function is a strong predictor of post-operative mortality.224
In patients with COPD and in smokers, pulmonary function
is signiﬁcantly reduced in 23e36%, leading to oxygenation
problems during peri-operative single-lung ventilation,
prolonged post-operative ventilatory support, and pneu-
monia.225 Pre-operative spirometry and blood gas analysis
can detect pulmonary compromise, and appropriate respi-
ratory training programmes and medical treatment can be
initiated to improve lung function. Pre-existing renal insuf-
ﬁciency is also a predictor of post-operative renal failure
and mortality and should be taken into account when
considering OR.226
In OR, proximal aortic cross-clamping causes increased
pre- and after-load on the heart. In addition, all organs and
tissues distal to the clamp will be excluded from the cir-
culation, including the spinal cord, visceral organs, kidneys,
and legs. The application of extracorporeal circulation with
distal aortic perfusion has reduced ischaemic complications.
Several techniques for extracorporeal circulation can be
used, including LHB by means of a left atriofemoral bypass
circuit or femoral veno-arterial bypass40,227 (see also Sec-
tions 2.4.2. and 3.3.2.2.).
During TAAA repair, the CA and the SMA should be
perfused with blood and both renal arteries should be
perfused with either cold crystalloid or blood to reduce
end-organ ischaemia.228 Despite protective measures such
as antegrade mesenteric perfusion, or retrograde perfusion
with sequential clamping, mucosal damage can still occur
and inﬂammatory reactions are induced.229
Risk factors for the development of SCI include prolonged
aortic cross clamp time, extensive aneurysmal disease,
aortic dissection, emergency surgery, internal iliac artery
exclusion, and previous abdominal aortic procedures.
Several strategies to limit neurological complications
include distal aortic perfusion, intercostal artery reimplan-
tation,37 CSF drainage,29,37,230 spinal cord cooling,231 and
assessment of spinal cord function peri-operatively30 (see
also Section 2.4.2.).
In two recent reviews, all available strategies to prevent
SCI were summarized.37,230 Despite lacking deﬁnitive proof
of efﬁcacy, compelling data exist to support the use of CSF
drainage along with methods of aortic perfusion distal to
the cross-clamp.230 A multimodal approach including CSF
drainage, maintenance of adequate MAP, LHB, and revas-
cularisation of intercostal arteries seems to be effective in
reducing the risk of SCI.232
The majority of publications on the results of open TAAA
repair originate from individual series, coming from highly
specialized centers.30,225,227 The results of these experienced
centres report mortality rates varying between 5% and 15%.
Major complications include respiratory failure (up to 60%),
neurological deﬁcits (3e18%), and renal failure (3e15%).
Outside highly specialized centres, mortality and morbidity
rates are almost doubled. A United States state-wide data-
base showed 30 day and 1 year mortality rates after elective
TAAA repair of 19% and 31%, respectively.233 These results
indicate that these complex procedures should be performed
only in specialized centres. Indeed, adequate staff support
and hospital and surgeon volume signiﬁcantly inﬂuence post-
operative survival. Another study234 clearly demonstrated
that less experience correlated with increased post-operative
mortality: in 1,542 operated patients, a signiﬁcant difference
(p< .001) in mortality was determined between low volume
hospitals (27.4%) and high volume hospitals (15%). Also, low
volume surgeons had signiﬁcantly (p< .001) higher mortality
rates (25.6%) compared with high volume surgeons (11.0%).
These volume outcome relationships were summarized in a
systematic review.235
3.4.2.3. Endovascular repair. Despite improvements in peri-
operative care and various surgical adjuncts, cardiopulmo-
nary, renal, and neurological complications such as SCI are
still common problems after open TAAA repair. Thus,
alternative managements have been sought, with two ap-
proaches currently under evaluation.
In the ﬁrst, deﬁned as the “hybrid approach”, visceral
perfusion was safeguarded by means of an OR extra-
anatomic bypass, followed by endovascular exclusion of
the entire aneurysm. This approach has the advantage of
limiting exposure to a laparotomy while avoiding a tho-
racotomy, although, this remains a considerable under-
taking in unﬁt patients. The issue of a single stage versus
two stage strategy has been debated, with higher mor-
tality and renal failure rates associated with one stage
procedures and an increased risk of death resulting from
rupture while awaiting the second stage.236 Early results,
in terms of mortality, SCI, and morbidity rates, generated
considerable enthusiasm.237 Recent data on 5 year
patency rates were also encouraging.238 Currently, the
hybrid technique is usually restricted to patients with no
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other reasonable options, such as emergency cases or high
risk patients with anatomy unfavourable for a branched
endograft.
The second technique (currently in evolution) is a total
endovascular repair using speciﬁcally constructed branched
modular aortic grafts.The rationale for this approach grew out
of the promising initial experience with fenestrated grafts,
which were developed to treat juxta-renal aneurysms by
endovascular means.239 Preservation of visceral ﬂow is ach-
ieved by means of either fenestrations or branches or a
combination of both on the component deployed in the region
of the visceral arteries. The aortic anatomy is still a limiting
factor, but the progress in imaging and device conception has
begun to overcome this challenge. Initial reports of the tech-
nique have all been from single centre studies and are non-
randomized.240e242 Many patients are deemed unﬁt for OR of
TAAA, particularly older patients, and this cohort represents
the group that have endovascular TAAA repair.
The published 30 day mortality rates range from 5.2% to
9.7% in the larger series (2.3%e2.6% for type IV TAAA).240e
243 Rates of SCI and cardiopulmonary and renal morbidities
appear to be largely in concordance with rates observed
following OR.240e243 The largest series of endovascular
repair of TAAA (406 patients) reported similar paraplegia
risks between endovascular and OR (4.3% endovascular
repair vs. 7.5% OR, respectively, p ¼ .08).241 The SCI risk
was associated with COPD, procedure duration, extent of
the aortic disease, and prior aortic surgery. Clinical
improvement after SCI has been reported.240
As in open procedures, patients with type I, II, or III
TAAAs have a higher risk of post-operative SCI and death,
when compared with type IV. In the short- to mid-term,
endovascular repair appears to be durable with accept-
able secondary re-intervention rates. One year survival
rates between 76% and 87% were reported and were
largely dependent on patient selection.239e243
The pre-operative clinical characteristics of the patients
investigated in these series may mean there is a negative
bias towards treating patients with greater comorbidities.
Therefore, the outcome of TAAA patients managed with a
minimally invasive approach, although associated with
positive results, still has a consistent rate of morbidity and
mortality. Patients undergoing these procedures, most of
whom have been rejected for OR, remain vulnerable in the
post-operative period. The relatively signiﬁcant risk of in
hospital death with advancing age and chronic renal failure
underscores the importance of excluding patients with poor
physiological status and limited life expectancy. By contrast,
the encouraging mid-term results suggest that this tech-
nique has a role in relatively unﬁt patients, especially when
performed in high volume centres.239e243
3.5. Inﬂammatory diseases of the descending thoracic
aorta
3.5.1. Takayasu arteritis. Takayasu arteritis (TA), also known
as pulseless disease, is a rare form of large vessel granu-
lomatous vasculitis with massive intimal ﬁbrosis and
vascular narrowing, or destruction of the elastic ﬁbres and
aneurysm formation.244
The pathogenesis of TA is poorly understood. Some evi-
dence suggests that a viral/bacterial infection of some kind,
in a person with other predisposing factors (such as genetic
disorders), may lead to this disease.245
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The American College of Rheumatology proposed the
following criteria for diagnosing TA:
1) Age of onset younger than 40 years.
2) Intermittent claudication.
3) Diminished brachial artery pulse.
4) Subclavian artery or aortic bruit.
5) Systolic blood pressure variation greater than 10 mm Hg
between arms, and
6) Angiographic (CT, MR) evidence of aortic or aortic
branch vessel stenosis.
The presence of three or more of these six criteria
demonstrated a high sensitivity and speciﬁcity for the
disease.245
The clinical manifestation of TA is typically described in
two phases: 1) a systemic “acute” phase, and 2) a “chronic”
phase. These two phases are not always distinct and pa-
tients may have features of both phases at the same time.
In the systemic phase, patients have symptoms and signs of
an active inﬂammatory disease. These may include
“constitutional symptoms” (fever, fatigue, weight loss),
arthritis, and non-speciﬁc aches and pains. This phase is
succeeded by the chronic phase, typical for symptoms
presenting in affected organs. Patients may experience
claudication of upper and/or lower limbs, symptoms
associated with cerebrovascular insufﬁciency (dizziness on
standing up, headaches, visual problems, transient ischae-
mic attack, or stroke), hypertension secondary to renal
artery involvement, or aortic regurgitation caused by
aortitis.
The thoracic aorta itself may be involved in the inﬂam-
matory process and develop either aneurysms or stenoses.
The diagnosis is conﬁrmed by CTA or MRA, which show
stenosis and dilation of the aorta, its branches, or both.
Thickening of the aortic wall detected by MRI or ultraso-
nography can precede the angiographic changes.
Treatment of TA is based principally on corticosteroids.
The great majority of patients respond to prednisone,
which is effective for the systemic symptoms and can
impede further progression of the vasculitis. The usual
starting dose is approximately 1 mg/kg of body weight per
day. Because of the signiﬁcant side effects of long-term
high dose prednisone use, the high starting dose is
tapered over several weeks to a dose that is more tolerable
for the patient, with respect to the decrease of C-reactive
protein and erythrocyte sedimentation rate (ESR). For life-
long treatment, methotrexate, azathioprine, and even
cyclophosphamide are sometimes used in addition to
prednisone.
There are few data in the literature to identify TA pa-
tients who require operation. Evidence for surgical or
endovascular repair of thoracic aortic disease in patients
with TA is extremely limited. It seems acceptable to main-
tain the same indications as in non-inﬂammatory disorders,
based on the risk of rupture related to aneurysm dimension,
and the presence of secondary organ vascular insufﬁciency.
In an 8 year study including 11 patients with TA (n ¼ 3),
GCA (n ¼ 2), and MFS (n ¼ 6), endovascular repair of
complicated aortic aneurysms proved safe and feasible.246
However long-term durability in this younger group of pa-
tients who have an ongoing risk of arterial degeneration
remains to be determined.
3.5.2. Giant cell arteritis. Giant cell arteritis (GCA), also
known as temporal arteritis or cranial arteritis,247 is a sys-
temic, inﬂammatory, vascular syndrome that affects the
aorta and its secondary and tertiary branches.
Although arteritis is a basis for aneurysms, dissections,
and stenotic lesions of the aorta and its major branches,
patients with GCA experienced similar mortality rates to the
general population of similar age and gender.248
The aetiology of GCA is unknown, but the pathogenesis is
similar to TA and involves a chronic inﬂammatory process,
which releases several cytokines, including T-lymphocyte
products interferon-gamma (IFN-gamma) and interleukin
(IL)-2. The T-cell clonal expansion suggests a speciﬁc anti-
genic response, which is still unclear (viral, bacterial, or
other). Concentric intimal hyperplasia is an important un-
derlying pathologic lesion in GCA.249
Clinical presentation varies from fever of unknown origin
to constitutional symptoms. Arterial lesions may be wide-
spread and the variable expression of GCA can be analyzed
according to the anatomical pattern of the arteries affected.
Polymyalgia rheumatica (PMR) and GCA may represent two
parts of a single disease spectrum, with GCA at the more
severe end. The two processes share certain constitutional
symptoms, including fatigue, weight loss, and fever.
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The following are criteria for GCA deﬁned by the Amer-
ican College of Rheumatology in 1990247: 1) age 50 years or
older; 2) new onset localised headache; 3) temporal artery
tenderness or decreased temporal artery pulse; 4) ESR of at
least 50 mm/h; and 5) abnormal arterial biopsy specimen
characterized by mononuclear inﬁltration or granulomatous
inﬂammation. The presence of at least three criteria yields a
diagnostic sensitivity of 93.5% and speciﬁcity of 91.2% when
compared with patients who were clinically classiﬁed as
having the disease. In the case of localisation of disease to
the temporal artery, biopsy is diagnostic in the majority of
cases, although its sensitivity declines with the initiation of
steroid therapy.250
A population based study over 50 years in patients with
GCA revealed a 31% cumulative frequency of large artery
complications, including aortic aneurysm or aortic dissec-
tion in 18%, and/or large artery stenosis in 11%.251 Presence
of thoracic aortic dissection was associated with markedly
increased mortality (median survival of only 1.6 years after
diagnosis of GCA).252
A comparative study suggested that a steroid regimen,
starting with 30e40 mg/day and tapering to 10 mg/day
within 6 months and to 5e7.5 mg/day within 1 year, is
effective and better tolerated in the patient population, than
the two higher dose regimens (40e60 or >60 mg/day).253
In refractory cases, the use of immunosuppressants, such as
methotrexate (15e25 mg/week) or azathioprine (2 mg/kg/
day), as potentially steroid-sparing disease controlling drugs,
has been considered and has shown conﬂicting results.254 The
newer tumour necrosis factor antagonists are being evaluated
in clinical trials, but initial studies of inﬂiximab did not show
promising results.254 Encouraging results have been reported
from the use of low dose aspirin for prevention of visual loss
and stroke in patients with GCA.255
Indications for surgical or endovascular repair in patients
with GCA are similar to non-inﬂammatory disorders, and the
decision in each patient is based on the risk of rupture related
to aneurysm dimension, and the presence of secondary organ
vascular insufﬁciency related to ﬁbrotic stenosis.
3.5.3. Behçet disease. This syndrome carries the name of
the Turkish dermatologist Hulusi Behçet, who, in 1937,
described a syndrome of recurrent aphthous ulcers, genital
ulcers, and uveitis.256 Vascular manifestations may vary and
depend on the type and location of the vessel involved. Any
large or small artery, vein, or organ may be involved in an
unpredictable combination. The most common vascular
complaints are secondary to venous thrombosis, often of
the superﬁcial veins.
Surgical and endovascular repair of aneurysm in Behçet
disease has been described as feasible. After surgical repair,
a high recurrence rate of anastomotic false aneurysm has
also been described, caused by the friability of the diseased
arteries. Moreover, any surgery may exacerbate Behçet
disease, so patients must be prescribed immunosuppressive
therapy before and after the surgical intervention.257
Because pseudoaneurysms may develop at arterial punc-
ture sites and veins may be quickly thrombosed after in-
jection of contrast material, angiography and venography
should be avoided whenever possible.258
3.5.4. Other inﬂammatory aortitides. Other chronic dis-
eases with potential inﬂammatory involvement of the
thoracic aorta include rheumatoid arthritis, sarcoidosis,
Cogan syndrome, Kawasaki disease, ankylosing spondylitis,
systemic lupus erythematosus, and Wegener’s gran-
ulomatosis.259 Some types of aortitides remain idiopathic.
Cardiovascular involvement in these patients is variable,
consisting of aortic valve regurgitation, aneurysm forma-
tion, dissection or stenosis of the aorta or its initial
branches. Localisation of the inﬂammatory disease at the
level of the aortic root with consequent aortic valve
regurgitation is the most common cardiovascular compli-
cation in these patients. The involvement of the DTA is
extremely rare but potentially more prone to rapid growth
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and rupture.260 In particular, systemic lupus erythematosus
has been suggested as possibly associated with thoracic AD,
especially in patients with persisting inﬂammation while on
chronic steroid therapy.260
3.6. Coarctation of the thoracic aorta in adults
3.6.1. Deﬁnition and diagnosis. Aortic coarctation is a
congenital defect characterized by stricture of the aortic
lumen typically located at the region of the ligamentum
arteriosum. This narrowing is usually localised, but may
involve other segments of the aorta such as the arch and,
less often, the abdominal aorta. There is signiﬁcant variation
in the degree of stenosis, extent of disease, and clinical
manifestations. Generally, an extensive collateral circulation
is present in adults.
Men are more often affected (2:1).261 Clinical manifesta-
tions include upper limb hypertension, weak and delayed
femoral pulses, and lower limb claudication. A thoracic bruit
may be present. In advanced cases, heart failure or intra-
cranial haemorrhage commonly develop. When the aortic
gradient is less pronounced or collaterals are well developed,
symptoms may be absent or mild. Other cardiovascular ab-
normalities include ventricular septal defects, bicuspid aortic
valve, sub-aortic stenosis, aortic medial disease, aortic arch
hypoplasia, patent ductus arteriosus, and intracranial aneu-
rysms.262 Adult patients most commonly present with
discrete forms of the disease, which may remain occult
during childhood and have no association with congenital
cardiac abnormalities, or present with recurrence after
intervention. There are currently no data on the exact inci-
dence of coarctation manifesting in adulthood.
Both CTA and MRI provide anatomical evidence of
coarctation and are the investigations of choice for deﬁni-
tive diagnosis. The aortic gradient may be directly measured
by catheterisation, or indirectly estimated using Doppler
echocardiography or cardiovascular MR.263
While TTE is usually diagnostic in children, it is often
inconclusive in adults. However, TOE is the method of
choice to evaluate cardiac sequelae such as ventricular
hypertrophy and left ventricular dysfunction, and associa-
tion with congenital cardiac abnormalities. CTA is a good
alternative to MRA, despite absence of functional infor-
mation. Diagnostic DSA and invasive gradient measure-
ments can be reserved for cases where non-invasive
methods fail to provide the necessary information for de-
cision making.
3.6.2. Management.Without treatment, mortality is 25% at
age 20, 50% at 32, and 75% at 46.264 Most patients die as a
result of heart failure, acute aortic syndromes, premature
CAD, or complications associated with valvular or cerebral
disease.264
After intervention, hypertension resolves in two thirds
of patients and the majority of them will beneﬁt from
improved ventricular function, reduced ventricular mass
and improved ascending aortic distensibility.265 Inter-
vention should be balanced between the anticipated
beneﬁts and the patient’s life expectancy, surgical risk
and comorbidities. In adults the pathological changes
resulting from aortic coarctation may no longer be
reversible.265,266
3.6.2.1. Indications for repair. Treatment is indicated for
symptomatic patients and should be considered for
asymptomatic patients with a trans-coarctation gradient
>20 mm Hg or persistent upper limb hypertension (systolic
pressure >140 mm Hg or diastolic pressure >90 mm Hg).
These thresholds are based on expert opinion only, but are
supported by clinical evidence suggesting that intervention
before large gradients are present may confer a higher
chance of reversing left ventricular dysfunction and pre-
venting irreversible loss of aortic wall compliance.265,266
There are two potential invasive treatment strategies,
open and endovascular surgery; however, given the rarity of
patients requiring invasive treatment, there are no ran-
domized trials comparing these two options. Case series
and non-randomized studies suggest marginally increased
peri-operative morbidity rates with OR, and greater recur-
rence rates after endovascular repair.265e267 Regardless of
treatment strategy, centralisation of treatment into expert
centres should be considered.
3.6.2.2. Open repair. OR is the classical method of treatment
for aortic coarctation. The most common techniques include
resection and end to end anastomosis, or an aortic interpo-
sition graft. Alternative techniques have been proposed, such
as patch or subclavian ﬂap aortoplasty, or ascending to
descending aortic bypass with or without valve replacement,
but are generally only performed in expert centres.267
Operative mortality after OR is generally very low (<1%).
Complications of OR include rebound hypertension, phrenic
and recurrent laryngeal nerve injury, recurrence of coarcta-
tion, and aneurysm or pseudo-aneurysm formation at the
patch site. Rarely, paraplegia and arm claudication (only if a
subclavian ﬂap is used) may occur.267
3.6.2.3. Endovascular repair. Anatomical suitability, with a
combination of good access vessels, and a short and
crossable lesion, is a necessary requirement for endovas-
cular repair. Operative mortality following endovascular
repair is very low (<1%). Rarely, aortic rupture (1e2% after
simple balloon dilatation), retrograde or antegrade
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dissection (<1%), stroke, or access problems may occur.
Such data make endovascular repair a valid alternative to
OR in native coarctations. Late complications of endovas-
cular repair include re-coarctation, which occurs more
often compared to OR and aneurysm formation (0e12%
after simple balloon dilatation).266e268 In adults, stent
placement appears to reduce late complications (particu-
larly aneurysm formation) and recurrence.267 Although
there is no current evidence to justify preferential use of
covered, straight, or tapered stents, these should be readily
available to expeditiously treat aortic rupture following
angioplasty.268 Provided anatomical suitability, an
endovascular-ﬁrst approach may be beneﬁcial for the
treatment of re-coarctation.269
3.7. Miscellanea
Genetic, congenital, and neoplastic pathologies can involve
the DTA.
3.7.1. Genetic syndromes.
3.7.1.1. Marfan syndrome. Marfan syndrome (MFS) is a
heritable connective tissue disorder. A mutation of the
ﬁbrillin-1 (FBN-1) gene on chromosome 15 has been found
in patients with MFS.
Estimates indicate that approximately 1 in 3,000e5,000
individuals have MFS.270 The mutation is inherited as a
dominant trait, so each parent with the condition has a 50%
risk of passing the genetic defect on to any child. Around
one in four patients has no family history, and the syndrome
is the result of a spontaneous mutation.
Recently a second type of the disorder (MFS type 2,
MFS2) has been identiﬁed.271 These mutations are in the
gene encoding transforming growth factor beta receptor 2
(TGFb R2), which has already been reported in LDS.272
A diagnosis of MFS can be established by clinical eval-
uation alone in the majority of cases. In 1998, the Ghent
criteria speciﬁed the characteristics of the phenotype and
genotype that can be assessed through history, physical
examination, imaging, and molecular genetic testing.270
More recently, an international expert panel has estab-
lished a revised nosology, which puts more weight on
aortic root aneurysm (or dissection) and ectopia lentis.
Then, in the absence of a family history, the diagnosis of
MFS can be made in the case of aortic root enlargement
and the presence of ectopia lentis; in the case of aortic
root enlargement and the presence of 7 or more points of
a systemic score; and in the case of aortic root enlarge-
ment and a probably causal FBN1 mutation. Finally, the
occurrence of ectopia lentis together with an FBN1 muta-
tion known to be associated with aortic dilatation is also
sufﬁcient to make the diagnosis. Together with a family
history, ectopia lentis or aortic root enlargement or a sys-
temic score 7 are sufﬁcient to make the diagnosis in
adults.270
The sensitivity of molecular genetic testing is substantial
yet imperfect for unidentiﬁed reasons. It may be justiﬁed by
atypical location or character of FBN1 pathogenic variants in
some individuals or to locus heterogeneity.273
MFS has a range of expressions, from mild to severe. The
most serious complications are defects of the heart valves
and aorta. The most severe cardiovascular complication is
acute type A aortic dissection, but type B dissection is also
common. AAA is rare.
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TTE measurement of the aortic root is very important for
the diagnosis and follow up of aortic complications in pa-
tients with MFS.274 Generalized aortic root dilatation is a
potent marker of an increased risk of subsequent aortic
complications in MFS, while dilatation limited to the sinuses
of Valsalva without including the aortic arch has a less
malignant prognosis. After diagnosis of aortic root/
ascending aortic dilatation is made, regular two dimensional
TTE is recommended at 6 months and then annually if no
further progression of the disease is demonstrated.
Some studies have shown that prophylactic beta-
adrenergic blockade is effective in slowing the rate of
aortic dilatation and reducing the development of aortic
complications in some patients with MFS.270 Some ran-
domized studies revealed that treatment with an angio-
tensin II receptor blocker may decrease aortic diameters in
adult patients with MFS.275 However, more recent data did
not show any advantages for angiotensin II receptor
blockers in comparison with atenolol among children and
young adults with MFS and large aortic root dilatation. A
signiﬁcant decrease in the degree of aortic root dilatation,
relative to body surface area, was observed with both
treatments.81,82
It is now essential to await results of ongoing large,
collaborative, randomized controlled trials276 with clinical
end points to assess the novel medical treatments in
MFS.
Determination of the size threshold in MFS for surgical
repair of thoracic aneurysm is not easy. Surgery is
generally recommended for a dilatation 50 mm, which
is a lower threshold in comparison with other patients
with thoracic aortic dilatation.54,274 Other factors that
may signiﬁcantly inﬂuence timing of aortic surgery
include: 1) rate of growth >2 mm per year; 2) presence
of signiﬁcant aortic regurgitation; and 3) family history of
dissection, especially if dissection occurred at aortic
diameter 50 mm. In cases with borderline indication
(diameter 45 mm), a well deﬁned increase in aortic
diameter >3 mm/year (on repeated measurements using
the same imaging technique, measured at the same
aortic level with side by side comparison and conﬁrmed
by another technique) may be an indication for surgical
treatment.
Surgery to the aortic root and thoracic and thoraco-
abdominal aorta has resulted in signiﬁcantly prolonged
life expectancy in many patients. The evidence for thoracic
endovascular repair in MFS is much more limited, with only
small series and registry or case reports including a het-
erogeneous group of patients with only short-term follow
up.193 More recently, particularly in patients with an
increased surgical risk because of redo sternotomy or tho-
racotomy, a gradual move to endovascular repair has been
observed, but this approach cannot be recommended for
routine use in patients with MFS.
Women with MFS are at high risk of aortic dissection in
pregnancy even in the absence of pre-conception aortic
root/ascending aorta dilatation. Although women with
aortic root dilatation of <40 mm usually tolerate
pregnancy well, with good maternal and foetal outcomes,
they should be advised regarding the risk of pregnancy to
both mother and foetus. Patients who have aortic root
dilatation >40 mm are recommended to avoid
pregnancy.277
3.7.1.2. Loeys-Dietz syndrome. Loeys-Dietz syndrome (LDS)
is an autosomal dominant genetic syndrome caused by
mutations in the genes encoding transforming growth
factor beta receptor 1 (TGFb R1) or 2 (TGFb R2).278 Given
that this syndrome was only recently described, its inci-
dence is currently unknown. Four main characteristics are
commonly seen in individuals with LDS: 1) arterial tortu-
osity (twisting or spiralled arteries), most often occurring in
the vessels of the neck; 2) hypertelorism (widely spaced
eyes); 3) biﬁd (split) or broad uvula; and 4) aneurysms
(although most often observed in the aortic root leading to
AD, can also be found in other arteries throughout the
body).
Cardiovascular involvement in LDS has been reported as
very aggressive with aneurysm formation and dissection/
rupture at a young age. Aortic root aneurysms are common
and often lead to AD. Aneurysms of the ascending or DTA
are less often seen and are seldom isolated. In the initial
clinical series,279 mean age at ﬁrst dissection was 26 years,
dissection occurred at aortic diameters as small as 39 mm
and the median age of death was 37 years.
Currently suggested criteria for elective intervention for
asymptomatic aneurysms in adults with LDS include an
aortic diameter >40 mm for the aortic root and abdominal
aorta,280 >50 mm for the DTA, and/or rapid expansion
(>5 mm/year) regardless of location. Considering that
dissection has been reported in aneurysms <40 mm in
diameter, even these criteria might not eliminate the risk of
dissection or death, and earlier interventions might be
indicated, depending on family history or an evaluation of
the risks and beneﬁts of surgery. A strategy of early and
aggressive surgical intervention seems to be justiﬁed,
especially given the typically young age of these patients,
the generalized tolerance of surgery, and the rarity of
complications related to tissue fragility.281 A deﬁnite
threshold diameter for intervention in cases of TAA has not
been established and the matter requires further investi-
gation with larger series.
3.7.1.3. Ehlers-Danlos syndrome. Ehlers-Danlos syndrome
(EDS) is a group of disorders that share common features
including easy bruising, joint hypermobility, skin hyper-
elasticity or laxity, and weakness of tissues, including
arteries.
In the vascular type of EDS (formerly called type IV),
spontaneous rupture of arteries and bowel are serious
manifestations that can lead to death. It is primarily
inherited as an autosomal dominant genetic disorder.
Arterial rupture may be preceded by aneurysm formation,
arteriovenous ﬁstulae, or dissection but may also occur
spontaneously. The anatomic locations of arterial rupture
are the thorax and abdomen (50%), head and neck (25%),
and extremities (25%). Such complications are dramatic and
often unexpected, presenting as sudden death, stroke and
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its neurological sequelae, acute abdomen, retroperitoneal
bleeding, and/or shock. The average age for the ﬁrst major
arterial or gastrointestinal complication is 23 years, and the
life expectancy is only 48 years.282
Surveillance may include periodic arterial screening by
MRI or computed tomographic imaging with or without
contrast. A conservative approach is usually recom-
mended for vascular type of EDS; however, urgent sur-
gery may be required to treat potentially fatal
complications.
From a pharmacological point of view, a recent multi-
centre, randomized and blinded study suggested that cel-
iprolol, a b(1)-adrenoceptor antagonist with a b(2)-
adrenoceptor agonist action, prevents dissections and
arterial ruptures in patients with vascular EDS.283
A number of patients develop post-operative anastomotic
pseudoaneurysms despite utilisation of a number of pre-
cautions including delicate and atraumatic handling of tis-
sues, and sewing of anastomoses with pledgeted sutures.284
At present, knowledge of the use of stents to treat
vascular complications of EDS is insufﬁcient. Novel ap-
proaches using endovascular repair with coil embolisation
have also been attempted, with good results in selected
cases of ruptured pseudoaneurysms, visceral aneurysms,
and carotid-cavernous ﬁstulas. However, because of the risk
of arterial rupture following arterial puncture, indications
for endovascular aortic repair remain to be determined.285
Maternalmortality during pregnancy in the vascular type of
EDS is around 12%, because of uterine or vascular rupture,
particularly during the last trimester. To minimise the risks
related to contractions and achieve haemostasis, a Caesarean
section should be carried out before the onset of labour.286
3.7.1.4. Turner syndrome. Turner syndrome (TS) is a genetic
disorder of female development with cardinal features of
short stature and congenital cardiovascular defects. It is a
chromosomal condition in which all or part of one of the sex
chromosomes is absent. Analysis of cytogenetic screening
studies indicates that TS occurs in w1/200 conceptions but
only 1/2000 live female births, with congenital cardiovascular
defects leading to a high rate of foetal death.287
An epidemiological study of Danish and Swedish records
found the median age of onset of AD or rupture in TS to be
35 years, with a projected annual incidence of approxi-
mately 15 cases/100,000 for individuals <20 years of age,
73e78 cases/100,000 for women 20e40 years old, and
w50/100,000 for older women with TS. Of note, the inci-
dence of AD in the general Danish population was 6/
100,000 in the same study.287
Patients who develop AD have aortic valve disease and/
or coarctation in 10e25% of cases. While apparently all TS
patients younger than 20 years have some structural
congenital heart disease, about 10% of adults with TS that
have died from aortic dissection have no evidence of major
structural defects on autopsy.288
Evidence for regular screening for aortic disease in
women with TS is not available. A baseline cardiovascular
evaluation should be obtained at the time of diagnosis and
includes MRI in addition to echocardiography. These studies
should be repeated every 5e10 years, or earlier if clinically
indicated by pregnancy or by known risk factors for AD such
as hypertension, bicuspid aortic valve, or coarctation.288
A recent study investigating the effect of supra-
physiological doses of growth hormone to increase adult
height in patients with TS, which may have direct effects on
the cardiovascular system, revealed that this regimen
neither seems to affect ascending or DTA diameter beyond
the increase related to the larger body size nor does it
disproportionately affect cardiac dimensions.289
3.7.1.5. Familial thoracic aortic disease. A family pattern of
transmission of familial thoracic aortic aneurysm and
dissection has been described recently.62 Studies have
conﬁrmed the genetic nature of DTAAs in a large popula-
tion of affected patients and families, with an inherited
pattern for DTAA present in up to 21.5% of non-Marfan
patients. Patterns of inheritance and phenotypic features
among family clusters have also been identiﬁed.62 These
statistics underestimate the true prevalence of familial
aneurysm disease because many family members may
harbour unknown aneurysms. For this reason it is quite
likely that the true rate of inheritance of DTAA is even
higher than 20%.
Although certain chromosomal loci have been identi-
ﬁed, complete identiﬁcation of the genes leading to this
familial non-syndromic form of DTAA is still in the early
phase of investigation.290 Some families have not mapped
to either of these loci suggesting that additional loci may
contribute to the constellation of genes responsible for
aneurysmal predisposition. The predominant mode of in-
heritance is autosomal dominant, with reduced gene
penetrance in women. Variable expressivity and multiple
anatomic locations of familial arterial aneurysms have
been observed.
Patients with familial DTAA are signiﬁcantly younger at
the time of presentation than patients with sporadic TAAA,
but not as young as patients with MFS. The aortic growth
rate has been reported to be 2.1 mm/year, which is faster
when compared with sporadic DTAA patient growth
(1.6 mm/year), and MFS (1 mm/year).
The aggressive clinical course of this disease underscores
the importance of appropriate screening in extended rela-
tives of patients with familial non-syndromic DTAA. Sec-
ondary prevention strategies employed for patients with
MFS including angiotensin converting enzyme inhibitor
administration, should also be evaluated for patients with
early onset familial DTAA.
All ﬁrst degree relatives of patients considered to be part of
a familial aneurysm disordermay be considered for screening
imaging to evaluate for DTA and AAA at the age of 50, with
repeat surveillance at regular intervals (e.g. 2e3 years).
3.7.2. Aortic tumours. Primary tumours of the aorta are
rare and are usually malignant. The diagnosis may be
complicated as aortic tumours can clinically mimic het-
erogeneous conditions such as aneurysm, dissection, aortic
coarctation, ﬂoating thrombus, intrathoracic, abdominal or
retroperitoneal malignancies, and atherosclerotic
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peripheral vascular disease. The diagnosis is most often
made after surgery or at autopsy. Most of the cases
described in the literature are sarcomas and malignant
ﬁbrous histiocytomas.291 Aortic angiosarcomas occur more
often in the DTA.
A clinico-pathological classiﬁcation of aortic tumours
categorizes the lesions as intimal or mural (obstructive and
non-obstructive).292 Intraluminal tumours often give rise to
thromboembolism, whereas those arising from the media
and adventitia form aggressive mass lesions, which may
have intra- and extra-luminal extension. Clinical presenta-
tion and imaging ﬁndings are often non-speciﬁc. Symptoms
are typically the result of tumour embolisation, local mass
effect, or luminal obstruction causing claudication or sec-
ondary hypertension in the case of renal stenosis.292
Making a diagnosis is challenging. Aortic sarcomas can
easily be confused with aneurysmal disease or atheroscle-
rotic aorto-iliac occlusive disease. The diagnosis may be
based on a high index of suspicion and is generally
conﬁrmed by ﬂuorodeoxyglucose/positron emission to-
mography/CT (FDG PET/CT), which shows increased uptake
at the location of the tumour,293 and biopsy.
Evidence regarding the therapeutic management of
aortic tumours shows poor outcomes. Survival in patients
with malignant tumours has been very poor, whether or not
they tolerate surgical resection. Five year survival is re-
ported at 12% after surgical intervention, and only 8% after
conservative treatment.294
Endovascular repair is not recommended. Stent grafts do
not preclude the growth and metastatic potential of
IIb C
IIb C
ReferencesLevel of evidenceClassRecommenda?on 65
In paƟents with Marfan syndrome, trans-thoracic echocardiographic 
measurement of the aorƟc root should be considered for the diagnosis 
and follow up of aorƟc involvement 
IIa C 274
Recommenda?on 66 
In Marfan syndrome, use of prophylacƟc beta-adrenergic blockade and 
of angiotensin II receptor blockers should be considered 
IIa C 82,270
Recommenda?on 67 
In paƟents with Ehlers-Danlos syndrome, treatment with celiprolol 
should be considered to prevent dissecƟons and arterial ruptures 
IIa B 283
Recommenda?on 68 
PaƟents with Loeys-Dietz and Ehlers-Danlos syndromes should be 
considered for treatment in collaboraƟon with highly specialized 
referral centres 
IIa C 284
Recommenda?on 69 
All first degree relaƟves of paƟents considered to be part of a familial 
aneurysm disorder may be considered for screening with imaging for 
descending thoracic aorƟc and abdominal aorƟc aneurysms at the age 
of 50, repeated thereaŌer at regular intervals 
IIb C 62
Recommenda?on 70 
ReproducƟve health counselling by geneƟc specialists should be 
oﬀered to paƟents diagnosed with any geneƟc connecƟve Ɵssue 
disorder 
I C 271,272,278,279
Recommenda?on 71 
Women with a confirmed geneƟc connecƟve Ɵssue disorder should be
advised regarding the relaƟve risks of pregnancy to both mother and 
foetus 
I C 277,286,287
Recommenda?on 72 
In paƟents with geneƟc syndromes associated with thoracic  aorƟc 
aneurysm dilataƟon ≥50 mm, surgery should be considered 
IIa C
281
Recommenda?on 73 
In paƟents with a geneƟc syndrome and enlarged aorƟc diameter
<50 mm, surgery may be considered according to body surface area in 
paƟents of small stature or for rapid progression or more aggressive 
diseases or with a family history of dissecƟon 
Recommenda?on 74 
In paƟents with connecƟve Ɵssue disorder, endovascular repair may be 
considered in redo operaƟons or in emergencies as bridging procedures 
193,285
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neoplastic lesions despite angiographic exclusion.295 Endo-
vascular exclusion can be offered only for compassionate
use when repetitive tumour embolic events occur.
3.7.3. Floating thrombus. Floating thrombus is deﬁned as
the presence of mobile thrombus in the DTA that may be a
potential source of life threatening peripheral arterial
emboli to visceral organs or the lower limbs. This condition
may be related to a previously injured aortic wall (dissec-
tion, atherosclerosis, or trauma).
A ﬂoating thrombus in a healthy thoracic aorta is a rare
event, and is commonly associated with an underlying
thrombophilia. In many cases the pathophysiology/aeti-
ology remains unknown.
Prompt diagnosis and treatment are necessary to avoid
severe complications. The diagnosis of ﬂoating thoracic
aortic thrombus is usually made after debilitating embolic
events. TOE represents the non-invasive study of choice
to ﬁrst exclude a cardioembolic source, while also
providing a good view of the distal arch and DTA. CTA and
MRA can provide additional and more detailed
information.296,297
The treatment strategy for this disease remains contro-
versial and is determined by the location and extension of
the thrombus, presence of complications, the patient’s
comorbidities, and the physician’s preferences. Options
include anticoagulant therapy, aspiration thrombectomy,
surgical thrombectomy, or endovascular repair by covered
stent deployment.296
If anticoagulation is selected, a size reduction of
thrombus should be observed in a short time and heparin
treatment must be maintained or switched to oral anti-
coagulation until the thrombus is completely dissolved.
When no reduction in thrombus size is observed, or if the
thrombus appears mobile within the aortic lumen, a more
aggressive treatment strategy should be recommended. The
beneﬁts of an OR approach with thoracic aortic throm-
bectomy are debatable, as the operative risk is dispropor-
tionally high relative to the potential beneﬁt. Moreover, the
risk of a medical treatment failure leading to repeated
embolism is undetermined, with a few reports demon-
strating complete thrombus dissolution with anti-
coagulation alone.297 On the other hand, early intervention
with thoracic aortic thrombectomy has been shown to
prevent fatal recurrent embolic events.296
Less invasive surgical approaches have been proposed,
including TOE guided trans-aortic and trans-femoral balloon
thrombectomy, percutaneous catheter thrombo-aspiration,
and TOE guided thrombus exclusion using endovascular
covered stents.298 Endovascular exclusion of the thrombus
from the systemic circulation by stent graft deployment is
certainly an attractive approach in high risk surgical patients
with favourable anatomy, although the possibility of
thrombus fragmentation and dislodgement by catheter
manipulation should also be considered.
Follow up must include long-term anticoagulant therapy
and routine surveillance using TOE or CTA or MRI until all
thrombus has disappeared, as the long-term outcome re-
mains uncertain.
4. SURVEILLANCE
To prevent complications and ascertain therapeutic efﬁcacy,
it is suggested that all patients diagnosed with or treated
for DTA disease should undergo a strict programme of
systematic surveillance. Successful management and out-
comes are dependent not only on the initial treatment, but
also on adequate follow up and early diagnosis of compli-
cations. Although the therapeutic options differ among the
various DTA diseases, patient surveillance follows a similar
protocol (Fig. 3A and 3B, Table 3). These surveillance in-
tervals are based on several reported experiences, as no
deﬁnitive evidence exists.44,65,85,88,107,108,129,168,173,299
All patients with DTA disease require aggressive man-
agement of hypertension, secondary prevention of cardio-
vascular diseases, and close follow up to monitor the
evolution of the diseased aorta. In particular, conservatively
treated patients are prone to develop progression of dis-
ease195 and OR patients can develop anastomotic pseu-
doaneurysm, new para-anastomotic aneurysms, graft
infection or graft occlusion.299 TEVAR may result in stent
graft related complications such as endoleak, stent graft
migration, or stent graft collapse.106,107 The primary
importance of the surveillance protocols is to prevent these
complications.
CTA is the modality most often used for follow up in DTA
disease. ECG-gated CTAs have greatly improved imaging
quality by eliminating pulsation artefacts. This imaging mo-
dality may identify subtle aortic characteristics such as the
primary intimal tear in TBAD and ulcerative plaques in PAU
(see also Section 2.3.5.). An excellent assessment of the vessel
wall and aortic lumen, including the surrounding anatomy is
derived from multiplanar imaging, three dimensional recon-
struction and centre lumen line reconstruction.20,21
However, cumulative lifetime radiation exposure caused
by multiple CTA examinations must be taken into account
during planning of follow up. In addition, iodinated intra-
venous contrast agents are associated with nephrotoxic
effects. MRI can be used to avoid radiation and iodinated
contrast media.300 MRI compatible stent grafts are a pre-
requisite, as the presence of stainless steel implants causes
artefacts. In patients treated with thoracic aortic endog-
rafts, conventional chest X-rays can show stent graft
migration, collapse, or fracture. This is especially true
regarding follow up after TAI repair. Given the generally
young age of this subgroup of patients, concerns arise with
regard to the cumulative radiation and iodinated contrast
exposure required for long-term follow up. For these rea-
sons, MRA may also be used for surveillance when magnetic
resonance compatible stent grafts are employed.166
Therefore, it seems reasonable to adopt a combination of
a multi-view chest X-rays and MRA instead of CTA for long-
term imaging of these patients.151
In patients with inﬂammatory disease, infectious/in-
ﬂammatory activity can be visualized and followed using
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nuclear imaging with 18-ﬂuorodeoxyglucose (FDG) posi-
tron emission tomography (PET), or gallium 67 (67GA).301
In suspected aortic graft infection, the diagnostic perfor-
mance of FDG-PET is superior to that of CTA and is rec-
ommended in certain situations.301 Because these
modalities do not provide any morphological characteris-
tics of the aorta, they need to be combined with CTA or
MRI. Additional oesophagoscopy and bronchoscopy may
be required in evaluation of aorto-bronchial and/or aorto-
oesophageal ﬁstulae.
In patients with ATBAD managed medically, progressive
aneurysmal dilatation can develop over time.189 This dila-
tation may eventually lead to rupture and sudden death
during the chronic phase.173 In ATBAD, some predictors of
aortic growth, like the entry tear size and partial FL
thrombosis, are now identiﬁed.168,174 Patients with chronic
TBAD may develop progression of the initial dissection or a
secondary aortic dissection event like intramural haema-
toma. In addition, in ATBAD patients treated with TEVAR,
distal perfusion of the FL is often observed, and its role
remains poorly understood.191
Therefore, routine surveillance should consist of physical
examination, blood pressure control, and echocardiography,
and mainly be done with MRA or CTA, based on patient
characteristics (see also Table 3).
The natural history of both PAU and IMH is unclear
and patients with these conditions should have a close
surveillance protocol. Morphological changes can develop
over time,7,12,121 and patients with IMH and PAU
should have the same surveillance programme as those
with AD.
In patients with DTAAs or TAAAs, surveillance after initial
detection is similar to that for other DTA diseases (Table 3).
In this setting, the level of evidence remains low, despite
the higher incidence of aneurysms and experience reported
in the literature. In conservatively managed patients, the
mean aortic growth is about 1 mm/year, and is more
prominent in the DTA in which growth has been reported to
be 1.9 mm/year.65 Other factors inﬂuencing aortic growth
are initial diameter and the presence of connective tissue
disorders. Surveillance of patients diagnosed with aneu-
rysms will consist of imaging studies after 6 and 12 months,
and yearly thereafter. For small and stable aneurysms, the
surveillance interval can be reduced to every 2e3 years
(Table 5).
The surveillance of patients with thoracic aortic coarc-
tation should include an annual clinical evaluation (blood
pressure in upper and lower limbs) by the cardiologist
combined with echocardiography and additional aortic
imaging when indicated. Although uncommon, pregnant
patients with coarctation should be monitored carefully to
prevent complications. After coarctation repair, by surgery,
TEVAR, or balloon angioplasty, regular follow up exami-
nation is mandatory. Long-term complications may occur,
especially when the intervention has been performed in
neonates. It is imperative to minimise radiation, as the
patient population can be relatively young. MRI, which is
the most cost effective imaging modality, should be
Table 5. Suggested disease speciﬁc follow up protocol for conservative management.
Modalities Interval Indications for closer follow up or
potential intervention
ATBAD CT or MRI 3 m, 6 m, yearly
In stable condition after 3 years
follow up, the interval can be
extended to 2e3 years
Aortic growth >5 mm/year
Aortic diameter >50 mm
IMH CT or MRI 3 m, 6 m, yearly
In stable condition after 3 years
follow up, the interval can be
extended to 2e3 years
Extension of IMH
Presence of concomitant PAU
Aortic growth >5 mm/year
Aortic diameter >50 mm
PAU CT or MRI 3 m, 6 m, yearly
In stable condition after 3 years
follow up, the interval can be
extended to 2e3 years
Thoracic aortic aneurysm CT or MRI 6 m, 12 m, yearly
In stable condition after 3 years
follow up, the interval can be
extended to 2e3 years
Aortic growth >5 mm/year
Aortic diameter >50 mm
Thoraco-abdominal aneurysm CT or MRI 6 m, 12 m, yearly
In stable condition after 3 years
follow up, the interval can be
extended to 2e3 years
Aortic growth >5 mm/year
Aortic diameter >55 mm
Inﬂammatory disease CT or MRI, combined
with PET
Blood tests: white cell
count, CRP
3 m, 6 m, yearly
Thoracic coarctation CT or MRI On clinical indication
Aortic disease with connective
tissue disorders
CT or MRI 3 m, 6 m, yearly Aortic diameter >45 mm
Aortic growth >5 mm/year
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adopted routinely as the follow up screening test of
choice.302 More recently, a non-invasive method based on
computational ﬂuid dynamics and MR imaging, has been
proposed to estimate the pre- and post-operative hae-
modynamics for both native and recurrent coarctation
patients.303
In all patients with DTA diseases managed by OR, follow
up is similar (see Fig. 4). After a 6 month post-operative CT
scan, patients should have yearly CTA or MRI examinations.
The interval between scans may be lengthened after 3 years
of complication-free follow up.
TEVAR requires more intensive surveillance compared
with open treatment, because of potential stent graft
related complications such as endoleak, migration, and
collapse. Detection of type I and III endoleaks requires
prompt intervention, as does stent graft migration or
collapse. Type II and IV endoleaks may be followed by serial
CTA/MRI187,304 (see Fig. 5).
5. GAPS IN THE EVIDENCE
Robust evidence is still needed in many aspects of the
management of DTA pathologies. In numerous clinical
scenarios, adequate trials are lacking. In addition, because
of continuous technical innovation in endovascular repair,
clinical practice tends to follow technical developments
without robust evidence from randomized trials.
Randomized studies often yield conﬂicting results because
of technical evolution and growth in the participants’
experience. These overall guidelines include this section to
identify the most relevant gaps in the evidence.
5.1. General aspects
5.1.1. The value of glucocorticosteroids, mannitol, and
intrathecal techniques to prevent spinal cord
ischaemia needs clinical data to be deﬁnitively
adopted or rejected for clinical practice during OR of
DTA.
5.1.2. The value of MEP and SSEP in patients treated with
TEVAR is not clearly supported by clinical data.
5.1.3. The optimal brain protection strategy in patients
requiring open or endovascular repair for thoracic
aortic disease needs to be deﬁned.
5.2. Acute type B dissection
5.2.1. TEVAR indications for uncomplicated ATBAD need to
be elucidated by prospective and randomized
studies.
5.2.2. It would be useful to deﬁne early unfavourable
clinical and imaging signs and biomarkers as
ReferencesLevel of evidenceClassRecommenda?on 75
Computed tomographic aortography should be considered 
the first opƟon for imaging surveillance in the acute seƫng 
of paƟents with thoracic aorƟc diseases
IIa C 20
Recommenda?on 76 
MagneƟc resonance imaging should be considered as an
imaging modality to follow up paƟents with aorƟc endograŌs
IIa C 300
Recommenda?on 77 
In paƟents diagnosed with type B aorƟc dissecƟon, 
penetraƟng aorƟc ulcer, or intramural haematoma, rouƟne 
surveillance should be considered including physical 
examinaƟon, echocardiography and imaging with magneƟc 
resonance angiography or computed tomographic 
aortography 
IIa C 19,121,173,189
Recommenda?on 78 
For paƟents treated with endograŌs life-long imaging follow 
up with magneƟc resonance angiography or computed 
tomographic aortography should be considered 
IIa C 187
Recommenda?on 79 
Any early or late type I or III endoleak aŌer an endovascular
repair of the descending thoracic aorta should undergo 
prompt intervenƟon 
I C 187,304
Recommenda?on 80 
In paƟents with DTA pathology managed by open repair,
follow up imaging aŌer 6 months with computed 
tomography should be performed   
I C 129, 299
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Figure 4. OR.
Computed Tomograpic Angiography 
A?er 6 months
Treatment as required
Endovascular or open repair 
Annual CTA/MRI
A?er 3 years follow up, the
interval can be extended to 
2–3 years
GraŌ infecƟon
Occlusion
Anastomotic 
pseudoaneurysm
No signs of 
complicaƟons
GraŌ infecƟon
Occlusion
AnastomoƟc 
pseudoaneurysm
Para-anastomic 
aneurysm
Figure 4. Suggested surveillance algorithm after open repair.
Computed Tomograpic Angiography 
Within 1 month and 12 months a?er 
procedure
CTA/MRI at 3 and 
6 months
Annual CTA/ MRI
A?er 3 years follow-up, interval 
can be extended to 2–3 years
No endoleak
No signs of 
complicaƟons
Endovascular or open 
repair as required
Endoleak*  
(Other 
ComplicaƟons**)
Type II or 
Type IV
Type IB in 
DissecƟons
Type I and III
Stent graŌ 
migraƟon
Stent graŌ  
collapse
Aneurysm sac 
growth 
>10mm
Aneurysm sac  
growth <10mm
No endoleak 
or 
complicaƟons
Figure 5. Suggested surveillance algorithm after TEVAR. *Endoleak types: type I, direct ﬂow between endograft and aortic wall in the
proximal (type Ia) or distal sealing zone (type Ib); type II, blood ﬂow in the aneurysm sac, originating from side branches; type III, direct
ﬂow coming from overlapped segments or through a defect of the stent graft fabric; type IV, blood ﬂow into the aneurysm sac because of
the porosity of the graft fabric. ** Other complications should be managed accordingly.
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predictive factors to identify patients who can
beneﬁt the most from thoracic endografting.
5.3. Thoracic aortic rupture
5.3.1. There is no level A or B evidence for the bestmethodof
repair of ruptured thoracic aortic aneurysms. A few
non-consecutive studies report endovascular
techniques and compare these with earlier reports
using OR (level C). Intuitively, sealing an anatomically
suitable ruptured thoracic aneurysm via a femoral
approach with a stent graft without opening the
chest must put the patient at lower risk, and there
will therefore never be a randomized trial to
compare the two modalities. In addition, the number
of affected patients is too small to support a
randomized trial and patients are very difﬁcult to
recruit.
5.4. Blunt traumatic thoracic aortic injury
5.4.1. A randomized clinical trial is not justiﬁed to elucidate
the beneﬁt of TEVAR over OR in the acute setting.
5.4.2. No evidence supports the choice between open and
endovascular repair for chronic post-traumatic
pseudoaneurysms.
5.4.3. More information about the natural history of
chronic post-traumatic pseudoaneurysms is
needed. No clear criteria for repair have been
described. The protective role of severe
calciﬁcation remains uncertain.
5.4.4. A follow up programme for patients who have
been treated by TEVAR for TAI needs to be
established.
5.5. Chronic type B dissection
5.5.1. The advent of endovascular repair suggests that
TBAD may require an additional classiﬁcation with
respect to chronicity. A sub-category of sub-acute
dissection may reﬂect the ability of the aorta to
remodel between 2 and 12 weeks after the initial
dissection. Further evidence of aortic remodelling
after TEVAR and the natural history of sub-acute
dissection is required.
5.5.2. There is a lack of natural history data relating to
CTBAD in the era of modern medical therapy. Data
are required to deﬁne the incidence of aortic
related events, aortic growth rates, and FL
thrombosis rates. These data may inform the
threshold and indications for interventional
therapy. At present there are no conclusive data to
establish diameter thresholds for repair of TBAD.
5.5.3. The natural history of CTBAD may be related to
morphological features that could be deﬁned with
newer imaging techniques such as 4D MRA.
Research is awaited.
5.5.4. There is a lack of distinct evidence regarding early
outcomes following repair of CTBAD e either open
or endovascular. At present most data relate to a
mixture of thoracic pathologies and more
homogenous data series are required. There are only
a few series detailing the ability of OR to prevent
aortic related death in the mid- and long-term. There
are very few series detailing the ability of TEVAR to
prevent aortic related death in themid- and long-term.
5.6. Descending thoracic aortic aneurysm
5.6.1. Intervention in DTAA <55 mm may not afford a
survival beneﬁt. Outcomes of intervention need to
be exceptional to justify repair in the small
aneurysm group. The advent of TEVAR justiﬁes a
randomized prospective trial for small DTAA to
compare early TEVAR and surveillance only.
5.6.2. Long-term durability of thoracic endografting,
especially for DTAA repair, is not well
determined. More data are needed from case
series and case control studies to elucidate the
late complications and re-intervention rate
beyond 5 years follow up.
5.7. Thoraco-abdominal aneurysm
5.7.1. There is no level A or B evidence on the best method
of repair for elective TAAA.
5.8. Inﬂammatory diseases
5.8.1. A very low level of evidence is available for
determining indications for treating inﬂammatory
disease of the thoracic aorta. The same indications
are recommended as for elective repair of any
thoracic aortic disease, based on the risk of rupture
related to aneurysm dimension and the presence of
secondary end organ ischaemia. This is level C
evidence.
5.8.2. There is very poor evidence to support any speciﬁc
follow up regimen after surgical or endovascular
repair of cardiovascular disorders in patients with
systemic inﬂammatory diseases receiving steroid
therapy.
5.9. Coarctation
5.9.1. There is no high quality evidence regarding the ideal
treatment strategy for native or recurrent coarctation
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in adults. No randomized trials have compared open
with endovascular strategies and such a comparison
is impractical because of the rareness of the disease
and constant developments in endovascular
technology. Further comparative evidence from
case control studies and case series is required.
Long-term data regarding durability and late
complications following endovascular repair are
essential.
5.9.2. Concerning endovascular repair, no high quality
evidence supports the routine use of bare or
covered stents. A prospective randomized trial
could clarify the optimal strategy in patients with
native or recurrent coarctation, with attention to
the following endpoints: re-stenosis/aneurysm
formation at the treatment site, residual
hypertension, and progressive left ventricular
dysfunction.
5.9.3. Evidence suggests that persistent hypertension after
successful repair is a risk factor for premature
coronary and carotid obstructive disease,
persistent left ventricular function deterioration
and increased risk of aortic and cerebral aneurysm
rupture. Persistent hypertension may be
multifactorial, with abnormal aortic wall
compliance and baroreceptor dysfunction as
possible causes. Further research on this topic is
necessary to clarify the risk beneﬁt of intervention.
5.10. Miscellanea
5.10.1. No robust evidence is available to support a
threshold diameter for treating patients with
genetic syndromes associated with thoracic
aneurysm (a threshold of 50 mm is suggested,
with a threshold <50 mm in cases where the
rate of growth is >5 mm per year, or when
signiﬁcant aortic regurgitation or a family history
of dissection is present). Unfortunately, the level
of evidence for this suggestion cannot be higher
than Level C. More and larger series are needed.
5.11. Surveillance
5.11.1. Surveillance intervals are based on several reported
experiences, as no evidence is available. This is
particularly evident in patients treated for DTAA,
in which the level of evidence remains low
despite the higher incidence of aneurysms and
increasing experience reported in the literature
(see also Section 5.8.2.).
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